HUE057734T2 - Heterociklusos vegyületek és alkalmazásuk - Google Patents

Heterociklusos vegyületek és alkalmazásuk

Info

Publication number: HUE057734T2
Authority: HU; Hungary
Prior art keywords: application; heterocyclic compounds; heterocyclic; compounds
Prior art date: 2013-10-04

Application number

HUE14786409A

Other languages

English (en)

Inventor

Alfredo Castro

Catherine Evans

Somarajannair Janardanannair

Andre Lescarbeau

Tao Liu

Martin Tremblay

Original Assignee

Infinity Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-10-04

Filing date

2014-10-03

Publication date

2022-06-28

2014-10-03 Application filed by Infinity Pharmaceuticals Inc filed Critical Infinity Pharmaceuticals Inc

2022-06-28 Publication of HUE057734T2 publication Critical patent/HUE057734T2/hu

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Transplantation (AREA)
Hematology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Plural Heterocyclic Compounds (AREA)

HUE14786409A 2013-10-04 2014-10-03 Heterociklusos vegyületek és alkalmazásuk HUE057734T2 (hu)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US201361887259P	2013-10-04	2013-10-04
US201361888958P	2013-10-09	2013-10-09
US201461938026P	2014-02-10	2014-02-10

Publications (1)

Publication Number	Publication Date
HUE057734T2 true HUE057734T2 (hu)	2022-06-28

Family

ID=51743565

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE14786409A HUE057734T2 (hu)	2013-10-04	2014-10-03	Heterociklusos vegyületek és alkalmazásuk

Country Status (27)

Country	Link
US (6)	US9359365B2 (hu)
EP (2)	EP3964507A1 (hu)
JP (1)	JP6466924B2 (hu)
KR (1)	KR102365651B1 (hu)
CN (1)	CN105793255B (hu)
AU (1)	AU2014329392B2 (hu)
BR (1)	BR112016007467B1 (hu)
CA (1)	CA2925944C (hu)
CL (1)	CL2016000783A1 (hu)
CY (1)	CY1124998T1 (hu)
DK (1)	DK3052485T3 (hu)
EA (1)	EA201690713A1 (hu)
ES (1)	ES2900806T3 (hu)
HU (1)	HUE057734T2 (hu)
IL (1)	IL244818B (hu)
MX (2)	MX2021012208A (hu)
MY (1)	MY175778A (hu)
NZ (1)	NZ718430A (hu)
PE (1)	PE20160685A1 (hu)
PH (1)	PH12016500582B1 (hu)
PL (1)	PL3052485T3 (hu)
PT (1)	PT3052485T (hu)
SG (2)	SG11201602445SA (hu)
TW (1)	TWI657085B (hu)
UA (1)	UA121104C2 (hu)
WO (1)	WO2015051244A1 (hu)
ZA (1)	ZA201602220B (hu)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RS60205B1 (sr)	2005-12-28	2020-06-30	Vertex Pharma	Farmaceutske kompozicije amorfnog oblika n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida
BRPI0906474A2 (pt)	2008-01-04	2015-07-14	Intellikine Inc	Certas entidades químicas, composições e métodos
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN103648499B (zh)	2011-01-10	2017-02-15	无限药品股份有限公司	用于制备异喹啉酮的方法及异喹啉酮的固体形式
TW201311663A (zh)	2011-08-29	2013-03-16	Infinity Pharmaceuticals Inc	雜環化合物及其用途
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3964507A1 (en) *	2013-10-04	2022-03-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US9775844B2 (en)	2014-03-19	2017-10-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
MX370450B (es)	2014-10-07	2019-12-13	Vertex Pharma	Co-cristales de moduladores de regulador de conductancia de transmembrana en fibrosis quistica.
HK1261923A1 (zh)	2015-09-14	2020-01-10	Twelve Therapeutics, Inc.	异喹啉酮衍生物的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2018076060A1 (en)	2016-10-26	2018-05-03	Genea Ip Holdings Pty Ltd	Improved generation of muscle lineage cells and therapeutic uses thereof
CN108017641B (zh) *	2016-11-02	2021-01-05	深圳铂立健医药有限公司	吡唑并嘧啶化合物作为pi3k抑制剂及其应用
CN106769807A (zh) *	2016-12-07	2017-05-31	王兰英	一种利用流式细胞仪检测HeLa细胞凋亡的方法
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
EP3740468A4 (en)	2018-01-20	2021-10-06	Sunshine Lake Pharma Co., Ltd.	SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
WO2019228404A1 (zh) *	2018-05-31	2019-12-05	信达生物制药(苏州)有限公司	一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途
CN113423427A (zh)	2018-11-30	2021-09-21	凯麦拉医疗公司	Irak降解剂和其用途
WO2020119592A1 (zh) *	2018-12-12	2020-06-18	信达生物制药(苏州)有限公司	一种新颖的三并环结构化合物及其制备方法和用途
CN110025621A (zh) *	2019-03-13	2019-07-19	中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心)	替唑尼特和硝唑尼特在制备抗炎药物中的应用
AU2020288610A1 (en) *	2019-06-04	2022-01-27	Arcus Biosciences, Inc.	2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
WO2020264490A1 (en) *	2019-06-28	2020-12-30	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
CN112194659A (zh) *	2019-07-08	2021-01-08	浙江海正药业股份有限公司	炔类衍生物及其制备方法和用途
EP4017527A1 (en)	2019-08-22	2022-06-29	Juno Therapeutics, Inc.	Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
CN110627827B (zh) *	2019-09-11	2022-11-08	杭州澳赛诺生物科技有限公司	4-乙炔基-四氢吡喃或4-乙炔基哌啶的合成方法
WO2021127283A2 (en)	2019-12-17	2021-06-24	Kymera Therapeutics, Inc.	Irak degraders and uses thereof
US11779578B2 (en)	2019-12-17	2023-10-10	Kymera Therapeutics, Inc.	IRAK degraders and uses thereof
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
WO2022125497A1 (en)	2020-12-08	2022-06-16	Infinity Pharmaceuticals, Inc.	Eganelisib for use in the treatment of pd-l1 negative cancer
CA3202360A1 (en)	2020-12-30	2022-07-07	Nello Mainolfi	Irak degraders and uses thereof
CA3207049A1 (en)	2021-02-15	2022-08-18	Jared Gollob	Irak4 degraders and uses thereof
WO2022212890A1 (en) *	2021-04-02	2022-10-06	Endpoint Health Inc.	Companion diagnostic and therapies for dysregulated host response
KR20220138655A (ko) *	2021-04-06	2022-10-13	주식회사 온코크로스	신장 질환의 예방 또는 치료용 화합물
WO2022226052A1 (en) *	2021-04-20	2022-10-27	The Regents Of The University Of Michigan	Pi3k inhibitors, nanoformulations, and uses thereof
CN115873000B (zh) *	2021-09-28	2025-02-28	中山医诺维申新药研发有限公司	异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
KR20240110592A (ko)	2021-10-29	2024-07-15	카이메라 쎄라퓨틱스 인코포레이티드	Irak4 분해제 및 이의 합성
US12091411B2 (en)	2022-01-31	2024-09-17	Kymera Therapeutics, Inc.	IRAK degraders and uses thereof
CN117186072A (zh) *	2022-06-01	2023-12-08	安驰达生物医药技术(广州)有限公司	一种抑制磷脂酰肌醇-3-激酶γ亚型活性的化合物及其制备方法与应用
WO2025003769A2 (zh) *	2023-06-30	2025-01-02	杭州百新生物医药科技有限公司	芳杂环并吡咯烷酮类衍生物及其用途

Family Cites Families (778)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB812366A (en)	1955-08-18	1959-04-22	Wellcome Found	Improvements in and relating to derivatives of pyrimidine and the preparation thereof
GB937725A (en)	1960-05-11	1963-09-25	Ciba Ltd	Pyrazolo[3:4-d]pyrimidines
US3536809A (en)	1969-02-17	1970-10-27	Alza Corp	Medication method
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
DE2139107A1 (de)	1971-08-04	1973-02-15	Merck Patent Gmbh	Heterocyclisch substituierte adenosinverbindungen
US3845770A (en)	1972-06-05	1974-11-05	Alza Corp	Osmatic dispensing device for releasing beneficial agent
US3916899A (en)	1973-04-25	1975-11-04	Alza Corp	Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en)	1976-02-02	1977-02-22	Alza Corporation	Osmotic system having laminar arrangement for programming delivery of active agent
JPS5569437U (hu)	1978-11-06	1980-05-13
US4270537A (en)	1979-11-19	1981-06-02	Romaine Richard A	Automatic hypodermic syringe
IT1153216B (it)	1981-10-16	1987-01-14	Schering Ag	Procedimento per la preparazione di composti cianoeterociclici
DE3244594A1 (de)	1982-12-02	1984-06-07	Hoechst Ag, 6230 Frankfurt	1-phenylisochinolinderivate und verfahren zu ihrer herstellung, diese verbindung enthaltende pharmazeutische praeparate und deren anwendung
DE3406533A1 (de)	1984-02-23	1985-08-29	Boehringer Mannheim Gmbh, 6800 Mannheim	Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US5310731A (en)	1984-06-28	1994-05-10	Whitby Research, Inc.	N-6 substituted-5'-(N-substitutedcarboxamido)adenosines as cardiac vasodilators and antihypertensive agents
HU196714B (en)	1984-10-04	1989-01-30	Monsanto Co	Process for producing non-aqueous composition comprising somatotropin
US4795627A (en)	1984-10-18	1989-01-03	University Of Pittsburgh	Tritium labelled N-mustard type compounds and a process for their production
IE58110B1 (en)	1984-10-30	1993-07-14	Elan Corp Plc	Controlled release powder and process for its preparation
US4656159A (en)	1984-10-31	1987-04-07	Georgetown University	Galactose-C-6 nitrogen mustard compounds and their uses
JPS61109797A (ja)	1984-11-01	1986-05-28	Yuki Gosei Yakuhin Kogyo Kk	標識化ヌクレオチドおよび標識化ポリヌクレオチド
US4596556A (en)	1985-03-25	1986-06-24	Bioject, Inc.	Hypodermic injection apparatus
US5023252A (en)	1985-12-04	1991-06-11	Conrex Pharmaceutical Corporation	Transdermal and trans-membrane delivery of drugs
CA1283827C (en)	1986-12-18	1991-05-07	Giorgio Cirelli	Appliance for injection of liquid formulations
GB8704027D0 (en)	1987-02-20	1987-03-25	Owen Mumford Ltd	Syringe needle combination
GB8707053D0 (en)	1987-03-25	1987-04-29	Ici Plc	Anti-tumour agents
US4992445A (en)	1987-06-12	1991-02-12	American Cyanamid Co.	Transdermal delivery of pharmaceuticals
US5001139A (en)	1987-06-12	1991-03-19	American Cyanamid Company	Enchancers for the transdermal flux of nivadipine
US4941880A (en)	1987-06-19	1990-07-17	Bioject, Inc.	Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en)	1987-06-19	1988-12-13	Bioject, Inc.	Non-invasive hypodermic injection device
US4940460A (en)	1987-06-19	1990-07-10	Bioject, Inc.	Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en)	1988-03-16	1994-08-16	Canon Kabushiki Kaisha	Automatic exposure control device using plural image plane detection areas
US5073543A (en)	1988-07-21	1991-12-17	G. D. Searle & Co.	Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
WO1990003370A1 (en)	1988-09-28	1990-04-05	Microprobe Corporation	DERIVATIVES OF PYRAZOLO[3,4-d]PYRIMIDINE
FR2638359A1 (fr)	1988-11-03	1990-05-04	Tino Dalto	Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
WO1993019767A1 (en)	1992-04-07	1993-10-14	The Regents Of The University Of Michigan	Cd28 pathway immunoregulation
GB8827305D0 (en)	1988-11-23	1988-12-29	British Bio Technology	Compounds
IT1229203B (it)	1989-03-22	1991-07-25	Bioresearch Spa	Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en)	1989-07-07	1997-12-23	Novartis Inc	Sustained release formulations of water soluble peptides.
US5442039A (en)	1989-07-17	1995-08-15	The Dow Chemical Company	Mesogenic polycyanates and thermosets thereof
US5428125A (en)	1989-07-17	1995-06-27	The Dow Chemical Company	Mesogenic polycyanates and thermosets thereof
US5506347A (en)	1993-02-03	1996-04-09	Gensia, Inc.	Lyxofuranosyl analogues of adenosine
US5721356A (en)	1989-09-15	1998-02-24	Gensia, Inc.	Orally active adenosine kinase inhibitors
US5795977A (en)	1989-09-15	1998-08-18	Metabasis Therapeutics, Inc.	Water soluble adenosine kinase inhibitors
US5674998A (en)	1989-09-15	1997-10-07	Gensia Inc.	C-4' modified adenosine kinase inhibitors
US5763596A (en)	1989-09-15	1998-06-09	Metabasis Therapeutics, Inc.	C-4' modified adenosine kinase inhibitors
US5763597A (en)	1989-09-15	1998-06-09	Metabasis Therapeutics, Inc.	Orally active adenosine kinase inhibitors
US5646128A (en)	1989-09-15	1997-07-08	Gensia, Inc.	Methods for treating adenosine kinase related conditions
US5120548A (en)	1989-11-07	1992-06-09	Merck & Co., Inc.	Swelling modulated polymeric drug delivery device
US5064413A (en)	1989-11-09	1991-11-12	Bioject, Inc.	Needleless hypodermic injection device
US5312335A (en)	1989-11-09	1994-05-17	Bioject Inc.	Needleless hypodermic injection device
GB9009542D0 (en)	1990-04-27	1990-06-20	Beecham Group Plc	Novel compounds
US5733566A (en)	1990-05-15	1998-03-31	Alkermes Controlled Therapeutics Inc. Ii	Controlled release of antiparasitic agents in animals
GB9113137D0 (en)	1990-07-13	1991-08-07	Ici Plc	Thioxo heterocycles
US5563257A (en)	1990-08-20	1996-10-08	Boehringer Mannheim Gmbh	Phospholipid derivatives of nucleosides
DE4026265A1 (de)	1990-08-20	1992-02-27	Boehringer Mannheim Gmbh	Neue phospholipid-derivate von nucleosiden, deren herstellung sowie deren verwendung als antivirale arzneimittel
US5190521A (en)	1990-08-22	1993-03-02	Tecnol Medical Products, Inc.	Apparatus and method for raising a skin wheal and anesthetizing skin
US5652366A (en)	1990-09-25	1997-07-29	Rhone-Poulenc Rorer Pharmaceuticals Inc.	DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
US5561134A (en)	1990-09-25	1996-10-01	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
SG80526A1 (en)	1990-09-25	2001-05-22	Rhone Poulenc Rorer Int	Compounds having antihypertensive and anti- ischemic properies
US5527288A (en)	1990-12-13	1996-06-18	Elan Medical Technologies Limited	Intradermal drug delivery device and method for intradermal delivery of drugs
GB9103839D0 (en)	1991-02-23	1991-04-10	Smithkline Beecham Plc	Pharmaceuticals
ES2108120T3 (es)	1991-05-10	1997-12-16	Rhone Poulenc Rorer Int	Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
GB9118204D0 (en)	1991-08-23	1991-10-09	Weston Terence E	Needle-less injector
SE9102652D0 (sv)	1991-09-13	1991-09-13	Kabi Pharmacia Ab	Injection needle arrangement
US5272158A (en)	1991-10-29	1993-12-21	Merck & Co., Inc.	Fibrinogen receptor antagonists
US5580578A (en)	1992-01-27	1996-12-03	Euro-Celtique, S.A.	Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5916891A (en)	1992-01-13	1999-06-29	Smithkline Beecham Corporation	Pyrimidinyl imidazoles
MX9300141A (es)	1992-01-13	1994-07-29	Smithkline Beecham Corp	Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
DE4204032A1 (de)	1992-02-12	1993-08-19	Boehringer Mannheim Gmbh	Neue liponucleotide, deren herstellunmg sowie deren verwendung als antivirale arzneimittel
DE4204031A1 (de)	1992-02-12	1993-08-19	Boehringer Mannheim Gmbh	Neue lipidphosphonsaeure-nucleosid-konjugate sowie deren verwendung als antivirale arzneimittel
US5328483A (en)	1992-02-27	1994-07-12	Jacoby Richard M	Intradermal injection device with medication and needle guard
JPH05239036A (ja)	1992-02-27	1993-09-17	Nissan Chem Ind Ltd	含窒素複素環化合物の製造方法
WO1993018035A1 (en)	1992-03-04	1993-09-16	Abbott Laboratories	Angiotensin ii receptor antagonists
JP2737518B2 (ja)	1992-03-16	1998-04-08	富士通株式会社	赤外線検知器の冷却構造
US5294612A (en)	1992-03-30	1994-03-15	Sterling Winthrop Inc.	6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
GB9208135D0 (en)	1992-04-13	1992-05-27	Ludwig Inst Cancer Res	Polypeptides having kinase activity,their preparation and use
JPH07506252A (ja)	1992-04-24	1995-07-13	エス・アール・アイ・インターナシヨナル	真核細胞内でのイン・ビボ相同配列ターゲッティング
KR100271083B1 (ko)	1992-06-19	2000-11-01	데이비드 에스. 호이리스	열전 온도 안정화를 갖는 적외선 카메라(Infrared Camera with Thermoelectric Temperature Stabilization)
US5383851A (en)	1992-07-24	1995-01-24	Bioject Inc.	Needleless hypodermic injection device
US6057305A (en)	1992-08-05	2000-05-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Antiretroviral enantiomeric nucleotide analogs
US5569189A (en)	1992-09-28	1996-10-29	Equidyne Systems, Inc.	hypodermic jet injector
US5334144A (en)	1992-10-30	1994-08-02	Becton, Dickinson And Company	Single use disposable needleless injector
TW333456B (en)	1992-12-07	1998-06-11	Takeda Pharm Ind Co Ltd	A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
TW370529B (en)	1992-12-17	1999-09-21	Pfizer	Pyrazolopyrimidines
US5455258A (en)	1993-01-06	1995-10-03	Ciba-Geigy Corporation	Arylsulfonamido-substituted hydroxamic acids
US5591767A (en)	1993-01-25	1997-01-07	Pharmetrix Corporation	Liquid reservoir transdermal patch for the administration of ketorolac
IL108523A0 (en)	1993-02-03	1994-05-30	Gensia Inc	Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
GB9308957D0 (en)	1993-04-30	1993-06-16	Cancer Res Campaign Tech	Novel produgs
ATE293686T1 (de)	1993-06-04	2005-05-15	Us Navy	Verfahren zur selektiven stimulierung der t- zellproliferation.
US6087324A (en)	1993-06-24	2000-07-11	Takeda Chemical Industries, Ltd.	Sustained-release preparation
EP0634402A1 (en)	1993-07-14	1995-01-18	Takeda Chemical Industries, Ltd.	Isochinolinone derivatives, their production and use
US5504103A (en)	1993-08-25	1996-04-02	Eli Lilly And Company	Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5525503A (en)	1993-09-28	1996-06-11	Dana-Farber Cancer Institute, Inc.	Signal transduction via CD28
DE4333761A1 (de)	1993-10-04	1995-04-06	Luitpold Pharma Gmbh	Heterocyclische Carbamate, Verfahren zu ihrer Herstellung und Arzneimittel
AU6672794A (en)	1993-11-05	1995-05-23	Biochem Pharma Inc.	Antineoplastic heteronaphthoquinones
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US5654307A (en)	1994-01-25	1997-08-05	Warner-Lambert Company	Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1995024176A1 (en)	1994-03-07	1995-09-14	Bioject, Inc.	Ampule filling device
US5466220A (en)	1994-03-08	1995-11-14	Bioject, Inc.	Drug vial mixing and transfer device
US6632789B1 (en)	1994-04-29	2003-10-14	The United States Of America As Represented By The Secretary Of The Navy	Methods for modulating T cell responses by manipulating intracellular signal transduction
DE4418690A1 (de)	1994-05-28	1996-01-11	Boehringer Mannheim Gmbh	Neue Lipidester von Nucleosid-Monophosphaten und deren Verwendung als immunsuppressive Arzneimittel
IT1270594B (it)	1994-07-07	1997-05-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5756502A (en)	1994-08-08	1998-05-26	Warner-Lambert Company	Quinazolinone derivatives as cholyecystokinin (CCK) ligands
US6323201B1 (en)	1994-12-29	2001-11-27	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
US5599302A (en)	1995-01-09	1997-02-04	Medi-Ject Corporation	Medical injection system and method, gas spring thereof and launching device using gas spring
US5863949A (en)	1995-03-08	1999-01-26	Pfizer Inc	Arylsulfonylamino hydroxamic acid derivatives
DK0819129T3 (da)	1995-04-03	2000-10-23	Novartis Ag	Pyrazolderivater og fremgangsmåde til deres fremstilling
US6312894B1 (en)	1995-04-03	2001-11-06	Epoch Pharmaceuticals, Inc.	Hybridization and mismatch discrimination using oligonucleotides conjugated to minor groove binders
ES2153031T4 (es)	1995-04-20	2001-05-16	Pfizer	Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
US5977061A (en)	1995-04-21	1999-11-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	N6 - substituted nucleotide analagues and their use
JPH08295667A (ja)	1995-04-27	1996-11-12	Takeda Chem Ind Ltd	複素環化合物、その製造法および剤
WO1996037777A1 (en)	1995-05-23	1996-11-28	Nelson Randall W	Mass spectrometric immunoassay
US5593997A (en)	1995-05-23	1997-01-14	Pfizer Inc.	4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
CN1522701A (zh)	1995-06-07	2004-08-25	G.D.ɪ��˾	环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
WO1996040256A1 (en)	1995-06-07	1996-12-19	G.D. Searle & Co.	Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
BR9608505A (pt)	1995-06-07	1999-07-06	G D Searle E Co	Terapia de combinação dos antagonistas espironolactona e angiotensina ii para o tratamento de insuficiència cardíaca congestiva
US5665721A (en)	1995-06-07	1997-09-09	Abbott Laboratories	Heterocyclic substituted cyclopentane compounds
EP0835101B1 (en)	1995-06-27	2004-06-09	Takeda Chemical Industries, Ltd.	Method of producing sustained-release preparation
TW448055B (en)	1995-09-04	2001-08-01	Takeda Chemical Industries Ltd	Method of production of sustained-release preparation
WO1997010221A1 (en)	1995-09-15	1997-03-20	Torrey Pines Institute For Molecular Studies	Synthesis of quinazolinone libraries
JP2909418B2 (ja)	1995-09-18	1999-06-23	株式会社資生堂	薬物の遅延放出型マイクロスフイア
US5763885A (en)	1995-12-19	1998-06-09	Loral Infrared & Imaging Systems, Inc.	Method and apparatus for thermal gradient stabilization of microbolometer focal plane arrays
JPH09143163A (ja)	1995-11-29	1997-06-03	Fuji Photo Film Co Ltd	含窒素ヘテロ芳香族アミド類の製造方法
EP0780386B1 (en)	1995-12-20	2002-10-02	F. Hoffmann-La Roche Ag	Matrix metalloprotease inhibitors
US5893397A (en)	1996-01-12	1999-04-13	Bioject Inc.	Medication vial/syringe liquid-transfer apparatus
US5980945A (en)	1996-01-16	1999-11-09	Societe De Conseils De Recherches Et D'applications Scientifique S.A.	Sustained release drug formulations
US5747235A (en)	1996-01-26	1998-05-05	Eastman Kodak Company	Silver halide light sensitive emulsion layer having enhanced photographic sensitivity
DE19603576A1 (de)	1996-02-01	1997-08-07	Bayer Ag	Acylierte 4-Amino und 4-Hydrazinopyrimidine
CH690773A5 (de)	1996-02-01	2001-01-15	Novartis Ag	Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5763608A (en)	1996-02-05	1998-06-09	Hoechst Celanese Corporation	Process for preparing pyrimidine derivatives
US5914488A (en)	1996-03-05	1999-06-22	Mitsubishi Denki Kabushiki Kaisha	Infrared detector
US5872136A (en)	1996-04-03	1999-02-16	Merck & Co., Inc.	Arylheteroaryl inhibitors of farnesyl-protein transferase
WO1997036901A1 (en)	1996-04-03	1997-10-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
GB9607549D0 (en)	1996-04-11	1996-06-12	Weston Medical Ltd	Spring-powered dispensing device
GB9611460D0 (en)	1996-06-01	1996-08-07	Ludwig Inst Cancer Res	Novel lipid kinase
PL330814A1 (en)	1996-06-20	1999-06-07	Regents Board Of	Compounds for and methods of delivering pharmaceutical preparations and their application
US6264970B1 (en)	1996-06-26	2001-07-24	Takeda Chemical Industries, Ltd.	Sustained-release preparation
JP3195756B2 (ja)	1996-07-04	2001-08-06	公子吉水	潤滑補助体
FR2750862B1 (fr)	1996-07-12	1998-10-16	Dupin Jean Pierre	Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
TR199900066T2 (xx)	1996-07-18	1999-04-21	Pfizer Inc.	Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
SK21499A3 (en)	1996-08-23	2000-05-16	Pfizer	Arylsulfonylamino hydroxamic acid derivatives
US6419961B1 (en)	1996-08-29	2002-07-16	Takeda Chemical Industries, Ltd.	Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (en)	1996-10-09	1998-04-09	Sumitomo Pharmaceuticals Co., Ltd.	Sustained release formulation
US6342514B1 (en)	1996-10-23	2002-01-29	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US5990169A (en)	1996-10-23	1999-11-23	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US5922753A (en)	1996-10-23	1999-07-13	Zymogenetics, Inc.	Methods for treating bone deficit conditions with benzothiazole
US5965573A (en)	1996-10-23	1999-10-12	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US5919808A (en)	1996-10-23	1999-07-06	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US5948776A (en)	1996-10-23	1999-09-07	Zymogenetic, Inc.	Compositions and methods for treating bone deficit conditions
US6251901B1 (en)	1996-10-23	2001-06-26	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US6153631A (en)	1996-10-23	2000-11-28	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
US5994358A (en)	1996-10-23	1999-11-30	Zymogenetics, Inc.	Compositions and methods for treating bone deficit conditions
ATE272394T1 (de)	1996-10-31	2004-08-15	Takeda Chemical Industries Ltd	Zubereitung mit verzögerter freisetzung
US5858753A (en)	1996-11-25	1999-01-12	Icos Corporation	Lipid kinase
US5977134A (en)	1996-12-05	1999-11-02	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU7624798A (en)	1996-12-06	1998-06-29	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1 beta converting enzyme
KR20000057693A (ko)	1996-12-20	2000-09-25	다케다 야쿠힌 고교 가부시키가이샤	지효성 제제의 제조 방법
US6093737A (en)	1996-12-30	2000-07-25	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU5131998A (en)	1997-01-06	1998-08-03	Pfizer Inc.	Cyclic sulfone derivatives
JPH10206995A (ja)	1997-01-21	1998-08-07	Konica Corp	ハロゲン化銀写真感光材料
US5891474A (en)	1997-01-29	1999-04-06	Poli Industria Chimica, S.P.A.	Time-specific controlled release dosage formulations and method of preparing same
IL131042A (en)	1997-02-03	2004-07-25	Pfizer Prod Inc	Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them
JP2000507975A (ja)	1997-02-07	2000-06-27	ファイザー・インク	Ｎ−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用
EP1017823B1 (en)	1997-02-07	2004-07-14	Princeton University	Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
CA2280151C (en)	1997-02-11	2005-12-13	Pfizer Inc.	Arylsulfonyl hydroxamic acid derivatives
US7863444B2 (en)	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
IL131582A0 (en)	1997-03-19	2001-01-28	Basf Ag	Pyrrolo [2,3d] pyrimidines and their use as tyrosine kinase inhibitors
US5993412A (en)	1997-05-19	1999-11-30	Bioject, Inc.	Injection apparatus
AU7449598A (en)	1997-05-23	1998-12-11	Nippon Shinyaku Co. Ltd.	Medicinal composition for prevention or treatment of hepatopathy
US6207679B1 (en)	1997-06-19	2001-03-27	Sepracor, Inc.	Antimicrobial agents uses and compositions related thereto
CA2303438A1 (en)	1997-09-09	1999-03-18	Bristol-Myers Squibb Pharma Company	Benzimidazolinones, benzoxazolinones, benzopiperazinones, indanones, and derivatives thereof as inhibitors of factor xa
DE69839887D1 (de)	1997-10-02	2008-09-25	Eisai R&D Man Co Ltd	Kondensierte pyridinderivate
US6649631B1 (en)	1997-10-23	2003-11-18	The Board Of Regents Of The University Of Texas System	Compositions and methods for treating bone deficit conditions
CA2309350C (en)	1997-11-12	2007-04-03	Mitsubishi Chemical Corporation	Purine derivatives and medicaments comprising the same as active ingredient
US6040321A (en)	1997-11-12	2000-03-21	Bristol-Myers Squibb Company	Aminothiazole inhibitors of cyclin dependent kinases
GB9725782D0 (en)	1997-12-05	1998-02-04	Pfizer Ltd	Therapeutic agents
US6184377B1 (en)	1997-12-15	2001-02-06	Sepracor Inc.	Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof
IT1298087B1 (it)	1998-01-08	1999-12-20	Fiderm S R L	Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6191170B1 (en)	1998-01-13	2001-02-20	Tularik Inc.	Benzenesulfonamides and benzamides as therapeutic agents
GB9801690D0 (en)	1998-01-27	1998-03-25	Pfizer Ltd	Therapeutic agents
US6613358B2 (en)	1998-03-18	2003-09-02	Theodore W. Randolph	Sustained-release composition including amorphous polymer
EP0945441A3 (de)	1998-03-27	2002-07-17	Degussa AG	Verfahren zur Herstellung von cyclischen 4-Oxoamidinen
US6127121A (en)	1998-04-03	2000-10-03	Epoch Pharmaceuticals, Inc.	Oligonucleotides containing pyrazolo[3,4-D]pyrimidines for hybridization and mismatch discrimination
US7715989B2 (en)	1998-04-03	2010-05-11	Elitech Holding B.V.	Systems and methods for predicting oligonucleotide melting temperature (TmS)
US6432970B2 (en)	1998-04-09	2002-08-13	Johns Hopkins University School Of Medicine	Inhibitors of hedgehog signaling pathways, compositions and uses related thereto
PA8469401A1 (es)	1998-04-10	2000-05-24	Pfizer Prod Inc	Derivados biciclicos del acido hidroxamico
PA8469501A1 (es)	1998-04-10	2000-09-29	Pfizer Prod Inc	Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
KR19990085365A (ko)	1998-05-16	1999-12-06	허영섭	지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
JP2000072773A (ja)	1998-08-28	2000-03-07	Zeria Pharmaceut Co Ltd	プリン誘導体
ATE310001T1 (de)	1998-09-18	2005-12-15	Abbott Gmbh & Co Kg	4-aminopyrrolopyrimidine als kinaseinhibitoren
HK1043128B (zh)	1998-12-19	2007-01-19	詹森药业有限公司	抗组胺的螺环化合物
US6383790B1 (en)	1999-01-11	2002-05-07	Princeton University	High affinity protein kinase inhibitors
CZ27399A3 (cs)	1999-01-26	2000-08-16	Ústav Experimentální Botaniky Av Čr	Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6248363B1 (en)	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6596497B1 (en)	1999-03-17	2003-07-22	New York Blood Center, Inc.	Screening of antiviral compounds targeted to the HIV-1 gp41 core structure
EP1040831A3 (en)	1999-04-02	2003-05-02	Pfizer Products Inc.	Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
SE515856C2 (sv)	1999-05-19	2001-10-22	Ericsson Telefon Ab L M	Bärare för elektronikkomponenter
BR0011063A (pt)	1999-06-03	2002-04-16	Knoll Gmbh	Compostos de benzotiazinona e benzoxazinona
US6387894B1 (en)	1999-06-11	2002-05-14	Pfizer Inc.	Use of CRF antagonists and renin-angiotensin system inhibitors
TWI262914B (en)	1999-07-02	2006-10-01	Agouron Pharma	Compounds and pharmaceutical compositions for inhibiting protein kinases
PE20010306A1 (es)	1999-07-02	2001-03-29	Agouron Pharma	Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
GB9919588D0 (en)	1999-08-18	1999-10-20	Hoechst Schering Agrevo Gmbh	Fungicidal compounds
DE19940860A1 (de)	1999-08-27	2001-03-01	Bayer Ag	Selektive Herbizide auf Basis eines substituierten Phenylsulfonyl aminocarbonyltriazolinons und Safenern II
DE19940859A1 (de)	1999-08-27	2001-03-01	Bayer Ag	Selektive Herbizide auf Basis eines substituierten Phenylsulfonylaminocarbonyltriazolinons und Safenern
ES2272319T3 (es)	1999-08-27	2007-05-01	Chemocentryx, Inc.	Compuestos heterociclicos y metodos para modular la funcion de cxcr3.
AU780846B2 (en)	1999-09-16	2005-04-21	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
US20050080138A1 (en)	1999-09-16	2005-04-14	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
US20070021493A1 (en)	1999-09-16	2007-01-25	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6921763B2 (en)	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
MXPA02002898A (es)	1999-09-17	2003-10-14	Abbott Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos.
DE60014130T2 (de)	1999-10-06	2006-03-09	Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield	Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
US6506769B2 (en)	1999-10-06	2003-01-14	Boehringer Ingelheim Pharmaceuticals, Inc.	Heterocyclic compounds useful as inhibitors of tyrosine kinases
IL149069A0 (en)	1999-10-13	2002-11-10	Univ Johns Hopkins Med	Regulators of the hedgehog pathway, compositions and uses related thereto
EP1227805B2 (en)	1999-10-14	2011-02-23	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6472153B1 (en)	1999-10-26	2002-10-29	Epoch Biosciences, Inc.	Hybridization-triggered fluorescent detection of nucleic acids
US7230000B1 (en)	1999-10-27	2007-06-12	Cytokinetics, Incorporated	Methods and compositions utilizing quinazolinones
US6545004B1 (en)	1999-10-27	2003-04-08	Cytokinetics, Inc.	Methods and compositions utilizing quinazolinones
US7671200B2 (en)	1999-10-27	2010-03-02	Cytokinetics, Inc.	Quinazolinone KSP inhibitors
US6660845B1 (en)	1999-11-23	2003-12-09	Epoch Biosciences, Inc.	Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof
IL133809A0 (en)	1999-12-30	2001-04-30	Yeda Res & Dev	Steroidal alkaloids and pharmaceutical compositions comprising them
GB0002032D0 (en)	2000-01-28	2000-03-22	Zeneca Ltd	Chemical compounds
US7217722B2 (en)	2000-02-01	2007-05-15	Kirin Beer Kabushiki Kaisha	Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
JP2001250689A (ja)	2000-03-07	2001-09-14	Toray Ind Inc	発光素子
AU2001249399A1 (en)	2000-03-24	2001-10-08	Cor Therapeutics, Inc.	Isoquinolone inhibitors of factor xa
US20050070578A1 (en)	2000-03-30	2005-03-31	Baxter Anthony David	Small organic molecule regulators of cell proliferation
US6683192B2 (en)	2000-03-30	2004-01-27	Curis, Inc.	Small organic molecule regulators of cell proliferation
US6613798B1 (en)	2000-03-30	2003-09-02	Curis, Inc.	Small organic molecule regulators of cell proliferation
ES2250377T5 (es)	2000-03-30	2010-04-06	Curis, Inc.	Moleculas organicas pequeñas reguladoras de la proliferacion celular.
US6683108B1 (en)	2000-03-30	2004-01-27	Curis, Inc.	Agonists of hedgehog signaling pathways and uses related thereto
US7115653B2 (en)	2000-03-30	2006-10-03	Curis, Inc.	Small organic molecule regulators of cell proliferation
US20020127625A1 (en)	2000-03-31	2002-09-12	Forskarpatent Is Syd Ab	Methods of diagnosing immune related diseases
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
PT3029041T (pt)	2000-04-25	2020-05-13	Icos Corp	Inibidores de fosfatidil-inositol 3-quinase delta humana
AU2001265137B2 (en)	2000-05-30	2007-06-14	Indiana University Research And Technology Corporation	Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
RU2003101969A (ru)	2000-06-27	2004-07-10	Дженелэбс Текнолоджиз, Инк. (Us)	Новые соединения, обладающие антибактериальной, противогрибковой и противоопухолевой активностью
US6534691B2 (en)	2000-07-18	2003-03-18	E. I. Du Pont De Nemours And Company	Manufacturing process for α-olefins
DE60132606T2 (de)	2000-09-20	2009-02-19	Merck & Co., Inc.	Isochinolinone als kalium-kanal-inhibitoren
ATE431355T1 (de)	2000-10-11	2009-05-15	Applera Corp	Fluoreszierende nukleobasekonjugate mit anionische linker
US20020173524A1 (en)	2000-10-11	2002-11-21	Tularik Inc.	Modulation of CCR4 function
JP2002131859A (ja)	2000-10-19	2002-05-09	Konica Corp	撮影用赤外感光性ハロゲン化銀写真感光材料及び赤外感光性ハロゲン化銀乳剤
US6890747B2 (en)	2000-10-23	2005-05-10	Warner-Lambert Company	Phosphoinositide 3-kinases
WO2002083143A1 (en)	2000-12-11	2002-10-24	Tularik Inc.	Cxcr3 antagonists
CN1492874A (zh)	2000-12-21	2004-04-28		大环内酯
KR100884877B1 (ko)	2000-12-28	2009-02-23	다이이찌 세이야꾸 가부시기가이샤	Ｖｌａ-４ 저해제
NZ526703A (en)	2001-01-22	2004-12-24	Merck & Co Inc	Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
US7105499B2 (en)	2001-01-22	2006-09-12	Merck & Co., Inc.	Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
GB0102239D0 (en)	2001-01-29	2001-03-14	Cancer Res Ventures Ltd	Methods of chemical synthisis
GB2373186A (en)	2001-02-23	2002-09-18	Astrazeneca Ab	Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
MXPA03008560A (es)	2001-03-22	2004-06-30	Abbot Gmbh & Co Kg	Pirazolopirimidinas como agentes terapeuticos.
DE10118698A1 (de)	2001-04-17	2002-11-07	Jerini Ag	Verfahren zur Immobilisierung und damit hergestellte Anordnungen von Verbindungen auf einer planaren Oberfläche
WO2002088025A1 (en)	2001-04-26	2002-11-07	New York University	Method for dissolving carbon nanotubes
US7405235B2 (en)	2001-05-04	2008-07-29	Paratek Pharmaceuticals, Inc.	Transcription factor modulating compounds and methods of use thereof
ES2282410T3 (es)	2001-05-08	2007-10-16	Kudos Pharmaceuticals Limited	Derivados de isoquinolinona como inhibidores de parp.
US7144903B2 (en)	2001-05-23	2006-12-05	Amgen Inc.	CCR4 antagonists
US6794379B2 (en)	2001-06-06	2004-09-21	Tularik Inc.	CXCR3 antagonists
JP2005505508A (ja)	2001-06-13	2005-02-24	ジーンソフトファーマシューティカルズインコーポレイテッド	抗感染活性を有するベンゾチオフェン化合物
US20030236198A1 (en)	2001-06-13	2003-12-25	Genesoft, Inc.	Antipathogenic benzamide compounds
JP2005505507A (ja)	2001-06-13	2005-02-24	ジーンソフトファーマシューティカルズインコーポレイテッド	抗感染活性を有するイソキノリン化合物
US20030114467A1 (en)	2001-06-21	2003-06-19	Shakespeare William C.	Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
US6596723B1 (en)	2001-07-16	2003-07-22	Essential Therapeutics, Inc.	Fungal efflux pump inhibitors
US20030220338A1 (en)	2001-07-16	2003-11-27	Watkins Will J.	Fungal efflux pump inhibitors
US6689782B2 (en)	2001-07-16	2004-02-10	Essential Therapeutics, Inc.	Fungal efflux pump inhibitors
AU2002322585A1 (en)	2001-07-20	2003-03-03	Adipogenix, Inc.	Fat accumulation-modulating compounds
AU2002327390B2 (en)	2001-07-27	2008-06-26	Curis, Inc.	Mediators of hedgehog signaling pathways, compositions and uses related thereto
EP1414443B1 (en)	2001-08-01	2006-11-15	Merck & Co., Inc.	BENZIMIDAZO 4,5-f\|ISOQUINOLINONE DERIVATIVES
AU2002327422A1 (en)	2001-08-03	2003-03-18	Abbott Laboratories	Method of identifying inhibitors of lck
DE10178132T1 (de)	2001-08-10	2016-06-23	Shionogi & Co., Ltd.	Antivirales Mittel
JP2003073357A (ja)	2001-09-03	2003-03-12	Mitsubishi Pharma Corp	アミド化合物を含有するＲｈｏキナーゼ阻害剤
CA2459583A1 (en)	2001-09-05	2003-03-13	Minerva Biotechnologies Corporation	Compositions and methods of treatment of cancer
WO2003024969A1 (en)	2001-09-14	2003-03-27	Merck & Co., Inc.	Tyrosine kinase inhibitors
CA2458926A1 (en)	2001-09-13	2003-03-13	Genesoft Pharmaceuticals, Inc.	Methods of treating infection by drug resistant bacteria
AUPR769501A0 (en)	2001-09-14	2001-10-11	Biomolecular Research Institute Limited	Cytokine receptor 1
US7269663B2 (en)	2001-09-28	2007-09-11	Intel Corporation	Tagging packets with a lookup key to facilitate usage of a unified packet forwarding cache
TWI330183B (hu)	2001-10-22	2010-09-11	Eisai R&D Man Co Ltd
AU2002363176B2 (en)	2001-11-01	2008-09-25	Janssen Pharmaceutica N.V.	Heteroaryl amines as glycogen synthase kinase 3Beta inhibitors (GSK3 inhibitors)
US20030113828A1 (en)	2001-11-09	2003-06-19	Ginsberg Mark H.	Compositions and methods for modulating Syk function
AU2002366103A1 (en)	2001-11-19	2003-06-10	Iconix Pharmaceuticals, Inc.	Modulators of rho c activity
WO2003043995A1 (en)	2001-11-20	2003-05-30	Cytokinetics, Inc.	Process for the racemization of chiral quinazolinones
ATE391505T1 (de)	2001-11-27	2008-04-15	Hoffmann La Roche	Benzothiazole derivative
WO2003048081A2 (en)	2001-12-04	2003-06-12	Bristol-Myers Squibb Company	Glycinamides as factor xa inhibitors
US20050107404A1 (en)	2001-12-06	2005-05-19	Fraley Mark E.	Mitotic kinesin inhibitors
CA2468156A1 (en)	2001-12-06	2003-06-19	Merck & Co., Inc.	Azolopyrimidinone compounds and their use
US20030158195A1 (en)	2001-12-21	2003-08-21	Cywin Charles L.	1,6 naphthyridines useful as inhibitors of SYK kinase
JP4085237B2 (ja)	2001-12-21	2008-05-14	日本電気株式会社	携帯電話の利用契約システムと通信方法
CA2469435A1 (en)	2001-12-21	2003-07-24	X-Ceptor Therapeutics, Inc.	Modulators of lxr
US7064218B2 (en)	2001-12-26	2006-06-20	Genelabs Technologies, Inc.	Aromatic compounds and poly(oxyalkylene) containing aromatic compounds possessing antibacterial, antifungal or antitumor activity
US7414036B2 (en)	2002-01-25	2008-08-19	Muscagen Limited	Compounds useful as A3 adenosine receptor agonists
AU2003213092A1 (en)	2002-02-15	2003-09-09	Smithkline Beecham Corporation	Syntheses of quinazolinones
US20040043959A1 (en)	2002-03-04	2004-03-04	Bloom Laura A.	Combination therapies for treating methylthioadenosine phosphorylase deficient cells
AU2003228283A1 (en)	2002-03-07	2003-09-22	X-Ceptor Therapeutics, Inc.	Quinazolinone modulators of nuclear receptors
US6995144B2 (en)	2002-03-14	2006-02-07	Eisai Co., Ltd.	Nitrogen containing heterocyclic compounds and medicines containing the same
AU2003225933A1 (en)	2002-03-22	2003-10-13	Cellular Genomics, Inc.	AN IMPROVED FORMULATION OF CERTAIN PYRAZOLO(3,4-d) PYRIMIDINES AS KINASE MODULATORS
JP4663986B2 (ja)	2002-03-26	2011-04-06	ツェントファーム・ゲーエムベーハー	フレデリカマイシン−誘導体
US7166293B2 (en)	2002-03-29	2007-01-23	Carlsbad Technology, Inc.	Angiogenesis inhibitors
AU2003226252A1 (en)	2002-04-04	2003-10-20	Cv Therapeutics, Inc.	Compounds dor increasing abca-1 expression useful for treating coronary artery disease and atherosclerosis
DE10217046A1 (de)	2002-04-17	2003-11-06	Bioleads Gmbh	Fredericamycin-Derivate
ATE404200T1 (de)	2002-04-22	2008-08-15	Univ Johns Hopkins Med	Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
WO2003090751A1 (en)	2002-04-26	2003-11-06	Pfizer Products Inc.	Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
US6794562B2 (en)	2002-05-01	2004-09-21	Stine Seed Farm, Inc.	Soybean cultivar 0332143
WO2003097053A1 (en)	2002-05-09	2003-11-27	Cytokinetics, Inc.	Compounds, compositions, and methods
MXPA04011074A (es)	2002-05-09	2005-06-08	Cytokinetics Inc	Compuestos de pirimidinona, composiciones y metodos.
TW200407143A (en)	2002-05-21	2004-05-16	Bristol Myers Squibb Co	Pyrrolotriazinone compounds and their use to treat diseases
JP2005536475A (ja)	2002-05-23	2005-12-02	サイトキネティクス・インコーポレーテッド	化合物、組成物、および方法
WO2004039774A2 (en)	2002-05-23	2004-05-13	Merck & Co., Inc.	Mitotic kinesin inhibitors
AU2003236527A1 (en)	2002-06-14	2003-12-31	Cytokinetics, Inc.	Compounds, compositions, and methods
RU2340605C2 (ru)	2002-06-27	2008-12-10	Ново Нордиск А/С	Арилкарбонильные производные в качестве терапевтических средств
US7265111B2 (en)	2002-06-27	2007-09-04	Sanofi-Aventis Deutschland Gmbh	Adenosine analogues and their use as pharmaceutical agents
EP2471533A1 (en)	2002-06-27	2012-07-04	Novo Nordisk A/S	Aryl carbonyl derivatives as therapeutic agents
DE10230917A1 (de)	2002-07-09	2004-02-05	Bioleads Gmbh	Fredericamycin-Derivate
BR0312752A (pt)	2002-07-10	2005-04-26	Applied Research Systems	Derivados de benzeno fundido de azolidinona-vinil
AU2003249244A1 (en)	2002-07-15	2004-02-02	Combinatorx, Incorporated	Methods for the treatment of neoplasms
JP2006503008A (ja)	2002-08-13	2006-01-26	ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー	マトリクスメタロプロテイナーゼ阻害物質としての４−ヒドロキシキノリン誘導体
CA2495661C (en)	2002-08-16	2011-06-14	Kinacia Pty Ltd.	Inhibition of phosphoinositide 3-kinase beta
JP2005536553A (ja)	2002-08-21	2005-12-02	サイトキネティクス・インコーポレーテッド	化合物、組成物および方法
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003265853A1 (en)	2002-08-29	2004-03-19	Curis, Inc.	Hedgehog antagonists, methods and uses related thereto
GB0220319D0 (en)	2002-09-02	2002-10-09	Cancer Res Campaign Tech	Enzyme activated self-immolative nitrogen mustard drugs
AU2003266668A1 (en)	2002-09-30	2004-04-23	Banyu Pharmaceutical Co., Ltd.	2-aminobenzimidazole derivative
AU2003301662A1 (en)	2002-10-21	2004-05-13	Bristol-Myers Squibb Company	Quinazolinones and derivatives thereof as factor xa inhibitors
JP2004161716A (ja)	2002-11-15	2004-06-10	Takeda Chem Ind Ltd	Ｊｎｋ阻害剤
CN1281590C (zh)	2002-11-27	2006-10-25	南京凯衡科贸有限公司	具有抑制血管生成活性的六员氨基酰胺类衍生物
WO2004058717A1 (en)	2002-12-20	2004-07-15	X-Ceptor Therapeutics, Inc.	Isoquinolinone derivatives and their use as therapeutic agents
US7365094B2 (en)	2002-12-23	2008-04-29	4Sc Ag	Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7247736B2 (en)	2002-12-23	2007-07-24	4Sc Ag	Method of identifying inhibitors of DHODH
WO2004056746A1 (en)	2002-12-23	2004-07-08	4Sc Ag	Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
SI1583562T1 (sl)	2003-01-06	2011-10-28	Angiochem Inc	AngioPep-1, sorodne spojine in njihove uporabe
FR2850022B1 (fr)	2003-01-22	2006-09-08	Centre Nat Rech Scient	Nouvelle utilisation de la mifepristone et de ses derives comme modulateurs de la voie de signalisation des proteines hedgehog et ses applications
WO2004069145A2 (en)	2003-02-07	2004-08-19	Dr. Reddy's Laboratories Ltd.	Anticancer compounds, process for their preparation and pharmaceutical compositions containing them
CA2517942A1 (en)	2003-03-06	2004-09-16	Dsm Ip Assets B.V.	Process for the preparation of an .alpha.-amino carbonyl compound
AR050920A1 (es)	2003-03-07	2006-12-06	Astrazeneca Ab	Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
US7550590B2 (en)	2003-03-25	2009-06-23	Takeda Pharmaceutical Company Limited	Dipeptidyl peptidase inhibitors
GB0306907D0 (en)	2003-03-26	2003-04-30	Angiogene Pharm Ltd	Boireductively-activated prodrugs
WO2004089297A2 (en)	2003-04-02	2004-10-21	Suntory Pharmaceutical Research Laboratories, Llc	Compounds and methods for treatment of thrombosis
WO2004092123A2 (en)	2003-04-10	2004-10-28	Microbia, Inc.	Inhibitors of fungal invasion
EP1622609A4 (en) *	2003-04-29	2008-09-03	Smithkline Beecham Corp	METHODS OF TREATING DEGENERATIVE DISEASES / LESIONS
MXPA05012465A (es)	2003-05-20	2006-01-30	Novartis Ag	Heterociclos de nitrogeno n-acilo como ligandos de receptores activados por el proliferador de peroxisoma.
US7022850B2 (en)	2003-05-22	2006-04-04	Bristol-Myers Squibb Co.	Bicyclicpyrimidones and their use to treat diseases
US7345046B2 (en)	2003-05-30	2008-03-18	Chiron Corporation	Heteroaryl-fused pyrimidinyl compounds as anticancer agents
EP1646615B1 (en)	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
WO2004113307A1 (ja)	2003-06-18	2004-12-29	Ube Industries, Ltd.	ピリミジン−４−オン化合物の製造方法
US7429596B2 (en)	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
EP1680125A1 (en)	2003-07-02	2006-07-19	Warner-Lambert Company LLC	Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor
EP2371835A1 (en)	2003-07-03	2011-10-05	The Trustees Of The University Of Pennsylvania	Inhibition of syk kinase expression
MXPA06000118A (es)	2003-07-08	2006-04-27	Novartis Ag	Compuestos de bencensulfonamino y composiciones farmaceuticas que contienen estos compuestos.
JP2005035933A (ja)	2003-07-15	2005-02-10	Takeda Chem Ind Ltd	含窒素縮合複素環化合物の製造方法
US20080118493A1 (en)	2003-07-15	2008-05-22	Beachy Philip A	Elevated Hedgehog Pathway Activity In Digestive System Tumors, And Methods Of Treating Digestive Sytem Tumors Having Elevated Hedgehog Pathway Activity
GB0317951D0 (en)	2003-07-31	2003-09-03	Trigen Ltd	Compounds
US7208601B2 (en)	2003-08-08	2007-04-24	Mjalli Adnan M M	Aryl and heteroaryl compounds, compositions, and methods of use
US7501538B2 (en)	2003-08-08	2009-03-10	Transtech Pharma, Inc.	Aryl and heteroaryl compounds, compositions and methods of use
WO2005016349A1 (en)	2003-08-14	2005-02-24	Icos Corporation	Methods of inhibiting leukocyte accumulation
US20050043239A1 (en)	2003-08-14	2005-02-24	Jason Douangpanya	Methods of inhibiting immune responses stimulated by an endogenous factor
BRPI0413563A (pt)	2003-08-15	2006-10-17	Irm Llc	compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
US7390820B2 (en)	2003-08-25	2008-06-24	Amgen Inc.	Substituted quinolinone derivatives and methods of use
WO2005044181A2 (en)	2003-09-09	2005-05-19	Temple University-Of The Commonwealth System Of Higher Education	Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
GB0321710D0 (en)	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
GB0322409D0 (en)	2003-09-25	2003-10-29	Astrazeneca Ab	Quinazoline derivatives
US8067608B2 (en)	2003-09-29	2011-11-29	The Johns Hopkins University	Hedgehog pathway antagonists
WO2005032343A2 (en)	2003-10-01	2005-04-14	The Johns Hopkins University	Hedgehog signaling in prostate regeneration neoplasia and metastasis
US20080057071A1 (en)	2003-10-20	2008-03-06	Watkins David N	Use Of Hedgehog Pathway Inhibitors In Small-Cell Lung Cancer
CA2545340A1 (en)	2003-11-10	2005-05-26	Synta Pharmaceuticals, Corp.	Fused heterocyclic compounds
WO2005049613A1 (en)	2003-11-14	2005-06-02	Merck Sharp & Dohme Limited	Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
US7368559B2 (en)	2003-11-14	2008-05-06	Diana Beardsley	FcγRIIA-specific nucleic acid interference
BRPI0416656A (pt)	2003-11-17	2007-01-16	Pfizer Prod Inc	compostos de pirrolopirimidina úteis no tratamento do cáncer
CA2546932A1 (en)	2003-11-25	2005-06-09	Chiron Corporation	Quinazolinone compounds as anticancer agents
EP1689719A1 (en)	2003-11-25	2006-08-16	Eli Lilly And Company	7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
JP2007513154A (ja)	2003-12-08	2007-05-24	サイトキネティクス・インコーポレーテッド	化合物、組成物及び方法
WO2005063258A1 (en)	2003-12-22	2005-07-14	Gilead Sciences, Inc.	Kinase inhibitor phosphonate conjugates
US20050152940A1 (en)	2003-12-23	2005-07-14	Medtronic Vascular, Inc.	Medical devices to treat or inhibit restenosis
KR100899245B1 (ko)	2003-12-23	2009-05-26	노파르티스 아게	비시클릭 헤테로시클릭 ｐ-38 키나제 억제제
WO2005061707A1 (ja)	2003-12-24	2005-07-07	Kyowa Hakko Kogyo Co., Ltd.	癌細胞のEg5阻害剤に対する感受性を判定する方法
US20050239809A1 (en)	2004-01-08	2005-10-27	Watts Stephanie W	Methods for treating and preventing hypertension and hypertension-related disorders
US20050214310A1 (en)	2004-01-23	2005-09-29	Seattle Genetics, Inc.	Melphalan prodrugs
JP2007520559A (ja)	2004-02-03	2007-07-26	アボット・ラボラトリーズ	治療薬としてのアミノベンゾオキサゾール類
JP4102939B2 (ja)	2004-02-13	2008-06-18	萬有製薬株式会社	縮環４−オキソ−ピリミジン誘導体
US7650848B2 (en)	2004-02-17	2010-01-26	University Of Florida Research Foundation, Inc.	Surface topographies for non-toxic bioadhesion control
US7117807B2 (en)	2004-02-17	2006-10-10	University Of Florida Research Foundation, Inc.	Dynamically modifiable polymer coatings and devices
US9016221B2 (en)	2004-02-17	2015-04-28	University Of Florida Research Foundation, Inc.	Surface topographies for non-toxic bioadhesion control
US20050187418A1 (en)	2004-02-19	2005-08-25	Small Brooke L.	Olefin oligomerization
EP1720874A4 (en)	2004-02-24	2010-03-03	Bioaxone Therapeutique Inc	4-SUBSTITUTED PIPERIDINE DERIVATIVES
US20070049593A1 (en)	2004-02-24	2007-03-01	Japan Tobacco Inc.	Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
JP2007523938A (ja)	2004-02-27	2007-08-23	エフ．ホフマン−ラ　ロシュ　アーゲー	ピラゾールの縮合誘導体
CN1960993A (zh)	2004-04-02	2007-05-09	Osi制药公司	6,6－双环取代的杂双环蛋白激酶抑制剂
US8057815B2 (en)	2004-04-19	2011-11-15	Portola Pharmaceuticals, Inc.	Methods of treatment with Syk inhibitors
EP1745041B1 (en)	2004-04-30	2012-06-20	Genentech, Inc.	Quinoxaline inhibitors of the hedgehog signalling pathway
RU2006142305A (ru)	2004-04-30	2008-06-10	Такеда Фармасьютикал Компани Лимитед (Jp)	Гетероциклическое амидное соединение и его применение в качестве ингибитора ммр-3
DE102004022897A1 (de)	2004-05-10	2005-12-08	Bayer Cropscience Ag	Azinyl-imidazoazine
ME02688B (me)	2004-05-13	2017-10-20	Icos Corp	Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
CA2566436C (en)	2004-05-13	2011-05-10	Vanderbilt University	Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en)	2004-05-25	2005-12-15	Icos Corporation	Methods for treating and/or preventing aberrant proliferation of hematopoietic
EP1750715A1 (en)	2004-06-04	2007-02-14	Icos Corporation	Methods for treating mast cell disorders
GB0412467D0 (en)	2004-06-04	2004-07-07	Astrazeneca Ab	Chemical compounds
US20050282834A1 (en)	2004-06-09	2005-12-22	Fady Malik	Compositions, devices and methods for treating cardiovascular disease
US7375102B2 (en)	2004-06-28	2008-05-20	Amgen Sf, Llc	Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use
US7939538B2 (en)	2004-06-28	2011-05-10	Amgen Inc.	Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases
WO2006023381A1 (en)	2004-08-16	2006-03-02	Taigen Biotechnology	Pyrimidinone compounds
US20060041128A1 (en)	2004-08-18	2006-02-23	Astrazeneca Ab	Selected fused heterocyclics and uses thereof
MX2007001953A (es)	2004-08-18	2007-05-09	Astrazeneca Ab	Enantiomeros de pirimidonas fusionadas seleccionadas y usos en el tratamiento y prevencion del cancer.
KR101487481B1 (ko)	2004-08-27	2015-01-28	인피니티 디스커버리, 인코포레이티드	사이클로파민 유사체 및 이들의 사용 방법
WO2006026597A2 (en)	2004-08-30	2006-03-09	Smithkline Beecham Corporation	Novel compositions and methods of treatment
US20090118261A1 (en)	2004-08-31	2009-05-07	Astrazeneca Ab	Quinazolinone derivatives and their use as b-raf inhibitors
KR101225018B1 (ko)	2004-09-02	2013-01-23	쿠리스 인코퍼레이션	헤지호그 신호전달에 대한 피리딜 억제제
BRPI0515030A (pt)	2004-09-09	2008-07-01	Us Gov Health & Human Serv	derivados de purina como agonistas de receptor de adenosina a3 e a1
GB0420722D0 (en)	2004-09-17	2004-10-20	Addex Pharmaceuticals Sa	Novel allosteric modulators
WO2006038865A1 (en)	2004-10-01	2006-04-13	Betagenon Ab	Nucleotide derivatives for the treatment of type 2 diabetes and other disorders
RU2007119637A (ru)	2004-10-28	2008-12-10	Айрм Ллк (Bm)	Соединения и композиции в качестве модуляторов hedgehog-пути
US8212011B2 (en)	2004-11-03	2012-07-03	University Of Kansas	Novobiocin analogues
US7622451B2 (en)	2004-11-03	2009-11-24	University Of Kansas	Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US8212012B2 (en)	2004-11-03	2012-07-03	University Of Kansas	Novobiocin analogues having modified sugar moieties
AU2005301957B2 (en)	2004-11-03	2012-02-23	Department Of Health And Human Services	Novobiocin analogues as anticancer agents
GB0425035D0 (en)	2004-11-12	2004-12-15	Novartis Ag	Organic compounds
EP1831225A2 (en)	2004-11-19	2007-09-12	The Regents of the University of California	Anti-inflammatory pyrazolopyrimidines
WO2006058088A2 (en)	2004-11-23	2006-06-01	Ptc Therapeutics, Inc.	Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
US20060156485A1 (en)	2005-01-14	2006-07-20	The Procter & Gamble Company	Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1855664A4 (en)	2005-01-19	2009-12-23	Merck & Co Inc	MITOTIC INHIBITORS OF KINESIN
CN101106998A (zh)	2005-01-19	2008-01-16	默克公司	有丝分裂驱动蛋白抑制剂
AU2006208084B2 (en)	2005-01-25	2012-07-26	Prolexys Pharmaceuticals, Inc.	Quinoxaline Derivatives as Antitumor Agents
US20070161644A1 (en)	2005-01-25	2007-07-12	Stockwell Brent R	Erastin analogs and uses thereof
GB0501999D0 (en)	2005-02-01	2005-03-09	Sentinel Oncology Ltd	Pharmaceutical compounds
EP1885356A2 (en)	2005-02-17	2008-02-13	Icos Corporation	Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
US7579348B2 (en)	2005-02-25	2009-08-25	Pgxhealth, Llc	Derivatives of 8-substituted xanthines
BRPI0607062A2 (pt)	2005-02-28	2009-08-04	Japan Tobacco Inc	composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos
US20090124654A1 (en)	2005-03-01	2009-05-14	Mjalli Adnan M M	Aryl and Heteroaryl Compounds, Compositions, Methods of Use
US7872050B2 (en)	2005-03-14	2011-01-18	Yaupon Therapeutics Inc.	Stabilized compositions of volatile alkylating agents and methods of using thereof
JP2006265107A (ja)	2005-03-22	2006-10-05	Kyowa Hakko Kogyo Co Ltd	緑内障治療剤
GB0506147D0 (en)	2005-03-24	2005-05-04	Merck Sharp & Dohme	Therapeutic agents
US20070066632A1 (en)	2005-03-25	2007-03-22	Scios, Inc.	Fused bicyclic inhibitors of TGFbeta
JP2008534479A (ja)	2005-03-25	2008-08-28	テイボテク・フアーマシユーチカルズ・リミテツド	Ｈｃｖの複素二環式阻害剤
EP1893605A2 (en)	2005-03-31	2008-03-05	AstraZeneca AB	Saminopyrimidine derivates with tie2 inhibiting activity
BRPI0608934A2 (pt)	2005-04-06	2010-02-17	Irm Llc	compostos e composições contendo diarilamina, e seu uso como moduladores de receptores nucleares de hormÈnios esteróides
KR100781704B1 (ko)	2005-04-20	2007-12-03	에스케이케미칼주식회사	피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물
CA2606399A1 (en)	2005-04-25	2006-11-02	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Scienc Es Of The Czech Republic	Use of compounds to enhance processivity of telomerase
US20090280153A1 (en)	2005-05-10	2009-11-12	Angiotech International Ag	electrical devices, anti-scarring agents, and therapeutic compositions
WO2006135479A2 (en)	2005-05-10	2006-12-21	Angiotech International Ag	Anti-scarring agents, therapeutic compositions, and use thereof
WO2006121522A2 (en)	2005-05-10	2006-11-16	Angiotech International Ag	Implantable sensors and pumps, anti-scarring agents, and therapeutic compositions
EP1881988A1 (en)	2005-05-11	2008-01-30	MERCK SHARP & DOHME LTD.	2,3-substituted fused bicyclic pyrimidin-4(3h)-ones modulating the function of the vanilloid-1 receptor (vr1)
GB0509573D0 (en)	2005-05-11	2005-06-15	Merck Sharp & Dohme	Therapeutic compounds
DE102005024017A1 (de)	2005-05-25	2006-11-30	Merck Patent Gmbh	Chinazolinone
CN100526315C (zh)	2005-06-16	2009-08-12	浙江医药股份有限公司新昌制药厂	N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
HRP20150832T1 (hr)	2005-06-22	2015-09-25	Chemocentryx, Inc.	Spojevi azaindazola i postupci njihove upotrebe
US7799795B2 (en)	2005-06-27	2010-09-21	Amgen Inc.	Aryl nitrile compounds and compositions and their uses in treating inflammatory and related disorders
WO2007008541A2 (en)	2005-07-08	2007-01-18	Kalypsys, Inc.	Cellular cholesterol absorption modifiers
BRPI0615524A2 (pt)	2005-07-11	2010-04-06	Devgen Nv	derivados da amida como inibidores da quinase
JP2009500437A (ja)	2005-07-11	2009-01-08	デブジェンエヌブイ	キナーゼ阻害剤としてのアミド誘導体
WO2007015877A2 (en)	2005-07-20	2007-02-08	Kalypsys, Inc.	Inhibitors of p38 kinase and methods of treating inflammatory disorders
US20070017915A1 (en)	2005-07-22	2007-01-25	Weder Donald E	Collapsible and/or erectable substantially egg-shaped container
GB0516723D0 (en)	2005-08-15	2005-09-21	Novartis Ag	Organic compounds
WO2007025090A2 (en)	2005-08-25	2007-03-01	Kalypsys, Inc.	Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
RU2008110941A (ru)	2005-08-25	2009-09-27	Ф.Хоффманн-Ля Рош Аг (Ch)	ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP1940805A4 (en)	2005-08-26	2009-11-11	Methylgene Inc	BENZODIAZEPIN AND BENZOPIPERAZINANALOGA AS INHIBITORS OF HISTONDEACETYLASE
WO2007025534A1 (de)	2005-09-01	2007-03-08	Bioagency Ag	Fredericamycin-derivate
AR056544A1 (es)	2005-09-29	2007-10-10	Wyeth Corp	Derivados fenilaminopropanol y metodos de uso de los mismos
CA2669736C (en)	2005-11-03	2017-02-21	Chembridge Research Laboratories, Inc.	Heterocyclic compounds as tyrosine kinase modulators
US20100152209A1 (en)	2005-11-04	2010-06-17	Hydra Biosciences Inc.	Compounds for Modulating TRPV3 Function
US20090156611A1 (en)	2005-11-11	2009-06-18	Licentia Ltd.	Mammalian hedgehog signaling modulators
CA2629814C (en)	2005-11-14	2013-12-31	Genentech, Inc.	Bisamide inhibitors of hedgehog signaling
BRPI0618622A2 (pt)	2005-11-17	2011-09-06	Osi Pharm Inc	composto, composição, e, uso de um composto
US20090088452A1 (en)	2005-11-22	2009-04-02	Coleman Paul J	Indole Orexin Receptor Antagonists
US20070265231A1 (en)	2005-11-30	2007-11-15	Michael Hofmann	Hydrazide Compounds for Combating Animal Pests
EP1956908A2 (en)	2005-12-08	2008-08-20	Cytokinetics, Inc.	Certain compositions and methods of treatment
JP2009520028A (ja)	2005-12-19	2009-05-21	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	Ｉｇｆｒ抑制剤および抗癌剤の併用
US7572809B2 (en)	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
US20090170834A1 (en)	2005-12-22	2009-07-02	Prolexys Pharmaceuticals, Inc.	Fused Pyrimidones and Thiopyrimidones, and Uses Thereof
WO2007076055A2 (en)	2005-12-22	2007-07-05	Entremed, Inc.	Compositions and methods comprising proteinase activated receptor antagonists
TW201307354A (zh)	2005-12-29	2013-02-16	Abbott Lab	蛋白質激酶抑制劑
AR059197A1 (es)	2006-01-25	2008-03-19	Smithkline Beecham Corp	Derivados de indazolo piridina para el tratamiento de hiv
WO2007089669A2 (en)	2006-01-26	2007-08-09	Wyeth	Processes for the preparation of compounds which modulate cell proliferation
CA2645137A1 (en)	2006-03-07	2007-09-13	James F. Blake	Heterobicyclic pyrazole compounds and methods of use
EP1998777A1 (en)	2006-03-20	2008-12-10	F. Hoffmann-La Roche AG	Methods of inhibiting btk and syk protein kinases
TW200800997A (en)	2006-03-22	2008-01-01	Astrazeneca Ab	Chemical compounds
SI2004683T1 (sl)	2006-03-24	2016-09-30	Biogen Hemophilia Inc.	Pc5 kot encim za obdelavo propeptida faktorja ix
CA2647543A1 (en)	2006-03-29	2007-11-08	Foldrx Pharmaceuticals, Inc.	Inhibition of alpha-synuclein toxicity
AU2007347115A1 (en)	2006-04-04	2008-10-23	The Regents Of The University Of California	PI3 kinase antagonists
EP2007737A2 (en)	2006-04-05	2008-12-31	AstraZeneca AB	Chemical compounds
US20090163525A1 (en)	2006-04-05	2009-06-25	Astrazeneca Ab	Substituted quinazolines with anti-cancer activity
KR20090006089A (ko)	2006-04-14	2009-01-14	노파르티스 아게	헤지호그 경로 관련 질환의 치료에서의 바이아릴카르복스아미드의 용도
WO2007121453A2 (en)	2006-04-17	2007-10-25	The Regents Of The University Of California	2-hydroxy-1-oxo 1,2 dihydro isoquinoline chelating agents
WO2007119055A1 (en)	2006-04-18	2007-10-25	Astrazeneca Ab	Quinazolin-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
ES2565238T3 (es)	2006-04-20	2016-04-01	Janssen Pharmaceutica N.V.	Inhibidores de la c-fms quinasa
GB0607948D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
PE20080361A1 (es)	2006-04-21	2008-06-03	Novartis Ag	Compuestos derivados de purina como activadores del receptor de adenosina a2a
GB0607950D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
US20090082370A1 (en)	2006-04-25	2009-03-26	Neil Thomas Thompson	Pharmaceutical Combinations of PK Inhibitors and Other Active Agents
US20090253718A1 (en)	2006-04-25	2009-10-08	Astex Therapeutics Limited	Pharmaceutical Compounds
DE102006020327A1 (de)	2006-04-27	2007-12-27	Bayer Healthcare Ag	Heterocyclisch substituierte, anellierte Pyrazol-Derivate und ihre Verwendung
UA93548C2 (uk)	2006-05-05	2011-02-25	Айерем Елелсі	Сполуки та композиції як модулятори хеджхогівського сигнального шляху
JP5225264B2 (ja)	2006-05-09	2013-07-03	ノベアメド・リミテッド	細胞増殖障害の処置
CN101448827A (zh)	2006-05-22	2009-06-03	阿斯利康(瑞典)有限公司	吲哚衍生物
GB0610242D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
ES2358043T3 (es)	2006-05-24	2011-05-05	Guardant S.R.L.	Anestésico local alcalinizado, en bolsa.
GB0610317D0 (en)	2006-05-24	2006-07-05	Medical Res Council	Antiparasitic compounds and compositions
US20080004253A1 (en)	2006-06-30	2008-01-03	Bryan James Branstetter	Thiazolopyrimidine modulators of TRPV1
WO2008011109A2 (en)	2006-07-20	2008-01-24	Amgen Inc.	Substituted pyridone compounds and methods of use
JP2009544329A (ja)	2006-07-27	2009-12-17	スミスクライン・ビーチャム・コーポレイション	ＫＳＰ阻害剤に対する感受性マーカーとしてのＨＳＰＡ１ａ
WO2008013987A2 (en)	2006-07-27	2008-01-31	Prolexys Pharmaceuticals, Inc.	N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
JP2009544664A (ja)	2006-07-28	2009-12-17	ノバルティスアクチエンゲゼルシャフト	脂質キナーゼ阻害剤としての２，４−置換キナゾリン
EP2061764B1 (en)	2006-08-22	2014-07-02	Technion Research & Development Foundation LTD.	Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr)
US7678803B2 (en)	2006-08-24	2010-03-16	Serenex, Inc.	Quinazoline derivatives for the treatment of cancer
CA2974246C (en)	2006-09-01	2020-02-25	Senhwa Biosciences, Inc.	Tricyclic heteroaryl compounds and their use as protein modulators
WO2008025755A1 (de)	2006-09-01	2008-03-06	Basf Se	Verwendung von n-haltigen heterozyklen in dermokosmetika
EP1903044A1 (en)	2006-09-14	2008-03-26	Novartis AG	Adenosine Derivatives as A2A Receptor Agonists
JP5306818B2 (ja)	2006-10-18	2013-10-02	武田薬品工業株式会社	縮合複素環化合物
CN101616931B (zh)	2006-10-31	2013-08-21	美国政府卫生与公共服务部	Smoothened多肽及使用方法
RU2333211C1 (ru)	2006-11-01	2008-09-10	Институт физиологически активных веществ Российской Академии наук	N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
US7772180B2 (en)	2006-11-09	2010-08-10	Bristol-Myers Squibb Company	Hepatitis C virus inhibitors
SG178786A1 (en)	2006-11-13	2012-03-29	Lilly Co Eli	Thienopyrimidinones for treatment of inflammatory disorders and cancers
WO2008063625A2 (en)	2006-11-20	2008-05-29	Adolor Corporation	Pyridine compounds and methods of their use
EP2094700B1 (en)	2006-11-20	2014-04-02	Novartis AG	Crystalline monotosylate salt of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
CA2671990A1 (en)	2006-12-06	2008-06-12	Boehringer Ingelheim International Gmbh	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN101605798A (zh)	2006-12-14	2009-12-16	第一三共株式会社	咪唑并噻唑衍生物
MX2009006864A (es)	2006-12-20	2009-08-28	Schering Corp	Inhibidores novedosos de c jun-n-terminal cinasas.
DK2114925T3 (da)	2006-12-22	2012-05-29	Ind Res Ltd	Azetidin-analoger af nucleosidase- og phosphorylase-inhibitorer
TWI433674B (zh)	2006-12-28	2014-04-11	Infinity Discovery Inc	環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092292A1 (en)	2007-01-17	2008-08-07	The Hong Kong University Of Science And Technology	Isoquinolone compounds as subtype-selective agonists for melatonin receptors mt1 and mt2
US20130116277A1 (en)	2007-01-22	2013-05-09	James T. Dalton	Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
JP5484914B2 (ja)	2007-01-22	2014-05-07	ジーティーエックス・インコーポレイテッド	核内受容体結合剤
US20170014401A1 (en)	2007-01-22	2017-01-19	Gtx, Inc.	Nuclear receptor binding agents
CA2676138A1 (en)	2007-01-26	2008-08-07	Irm Llc	Compounds and compositions as kinase inhibitors
AR065081A1 (es)	2007-01-29	2009-05-13	Xenon Pharmaceuticals Inc	Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica
NZ579356A (en)	2007-03-07	2012-04-27	Infinity Pharmaceuticals Inc	Cyclopamine lactam analogs and methods of use thereof
JP2010520295A (ja)	2007-03-07	2010-06-10	インフィニティ・ディスカバリー・インコーポレイテッド	へテロ環状シクロパミン類似体及びその使用方法
CN101686952A (zh)	2007-03-12	2010-03-31	Vm生物医药公司	新型钙离子通道调节剂
EP2134695A4 (en)	2007-03-14	2011-05-25	Exelixis Inc	HEMGE OF THE HEDGEHOG SIGNAL PATH
MY156814A (en)	2007-03-15	2016-03-31	Novartis Ag	Organic compounds and their uses
EP2139882B1 (en)	2007-03-23	2013-12-25	Amgen Inc.	3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
ES2563458T3 (es)	2007-03-23	2016-03-15	Amgen Inc.	Compuestos heterocíclicos y sus usos
EP2132207A2 (en)	2007-03-23	2009-12-16	Amgen Inc.	Heterocyclic compounds and their uses
US7867983B2 (en)	2007-03-29	2011-01-11	The University Of Connecticut	Methods to protect skeletal muscle against injury
EP1977765A1 (en)	2007-04-03	2008-10-08	Diatos	Peptide prodrugs
MX2009010536A (es)	2007-04-13	2009-10-22	Sanofi Aventis	Una sintesis de n-aminoindoles catalizada por un metal de transicion.
WO2008125014A1 (fr)	2007-04-13	2008-10-23	Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A.	Composés d'urée, leurs procédés de préparation et leurs utilisations pharmaceutiques
US20090054517A1 (en)	2007-04-20	2009-02-26	Lubahn Dennis B	Phytoestrogens As Regulators Of Hedgehog Signaling And Methods Of Their Use In Cancer Treatment
JP2010163361A (ja)	2007-04-27	2010-07-29	Dainippon Sumitomo Pharma Co Ltd	キノリン誘導体
CA2685753A1 (en)	2007-05-09	2008-11-20	Neuromed Pharmaceuticals Ltd.	Bicyclic pyrimidine derivatives as calcium channel blockers
US7960353B2 (en)	2007-05-10	2011-06-14	University Of Kansas	Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
CN101742911A (zh)	2007-05-17	2010-06-16	科泰克斯药品公司	用于增强谷氨酸能突触反应的二取代的酰胺
TW200902016A (en)	2007-05-22	2009-01-16	Taigen Biotechnology Co Ltd	Kinesin inhibitors
CA2688194A1 (en)	2007-05-23	2008-12-04	Siga Technologies, Inc.	Antiviral drugs for treatment or prevention of dengue infection
WO2008153701A1 (en)	2007-05-24	2008-12-18	Schering Corporation	Compounds for inhibiting ksp kinesin activity
US9603848B2 (en)	2007-06-08	2017-03-28	Senomyx, Inc.	Modulation of chemosensory receptors and ligands associated therewith
US7928111B2 (en)	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
US20110217300A1 (en)	2007-06-22	2011-09-08	Arqule, Inc.	Quinazolinone Compounds and Methods of Use Thereof
EP2173724B1 (en)	2007-06-22	2012-12-05	ArQule, Inc.	Quinazolinone compounds and methods of use thereof
WO2009002553A1 (en)	2007-06-25	2008-12-31	Prolexys Pharmaceuticals, Inc.	Methods of treating multiple myeloma and resistant cancers
US9138484B2 (en)	2007-06-25	2015-09-22	Endocyte, Inc.	Conjugates containing hydrophilic spacer linkers
CA2693142A1 (en)	2007-06-26	2008-12-31	Sanofi-Aventis	A regioselective metal catalyzed synthesis of annelated benzimidazoles and azabenzimidazoles
EP2170274A1 (en)	2007-07-02	2010-04-07	Technion Research and Development Foundation, Ltd.	Compositions, articles and methods comprising tspo ligands for preventing or reducing tobacco-associated damage
US20090012031A1 (en)	2007-07-03	2009-01-08	The Regents Of The University Of Michigan	EZH2 Cancer Markers
RU2345996C1 (ru)	2007-07-17	2009-02-10	Андрей Александрович Иващенко	Аннелированные азагетероциклические амиды, включающие пиримидиновый фрагмент, способ их получения и применения
CA2694218A1 (en)	2007-07-31	2009-02-05	Schering Corporation	Anti-mitotic agent and aurora kinase inhibitor combination as anti-cancer treatment
WO2009018811A1 (de)	2007-08-06	2009-02-12	Schebo Biotech Ag	Neue pharmazeutika, verfahren zu ihrer herstellung und ihre verwendung in der medizinischen therapie
WO2009021163A2 (en)	2007-08-08	2009-02-12	University Of Rochester	Enhancing gene transfer
WO2009042294A2 (en)	2007-08-10	2009-04-02	Burnham Institute For Medical Research	Tissue-nonspecific alkaline phosphatase (tnap) activators and uses thereof
EP2185570B1 (en)	2007-08-13	2014-03-19	Metabasis Therapeutics, Inc.	Novel activators of glucokinase
WO2009029617A1 (en)	2007-08-27	2009-03-05	Kalypsys, Inc.	Diarylamine-substituted quinolones useful as inducible nitric oxide synthase inhibitors
CN101854937B (zh)	2007-09-10	2013-03-27	波士顿生物医药公司	新的stat3途径抑制剂和癌症干细胞抑制剂
JP5227965B2 (ja)	2007-10-03	2013-07-03	独立行政法人理化学研究所	ニトロトリアゾール誘導体、およびそれを用いる化合物の製造方法
JP2011500657A (ja)	2007-10-15	2011-01-06	アストラゼネカアクチボラグ	組合せ０５９
AU2008321099A1 (en)	2007-11-13	2009-05-22	Icos Corporation	Inhibitors of human phosphatidyl-inositol 3-kinase delta
CA2705405A1 (en)	2007-11-22	2009-05-28	Boehringer Ingelheim International Gmbh	New compounds
EP2070932A1 (en)	2007-12-13	2009-06-17	4Sc Ag	Pyrazolotriazines
AU2008338963A1 (en)	2007-12-13	2009-06-25	Sri International	PPAR-delta ligands and methods of their use
CN101896472A (zh)	2007-12-13	2010-11-24	锡耶纳生物技术股份公司	Hedgehog途径拮抗剂及其治疗应用
ES2587738T3 (es)	2007-12-21	2016-10-26	Ucb Biopharma Sprl	Derivados de quinoxalina y quinolina como inhibidores de quinasa
AU2008345225A1 (en)	2007-12-21	2009-07-09	University Of Rochester	Method for altering the lifespan of eukaryotic organisms
US7960397B2 (en)	2007-12-28	2011-06-14	Institute Of Experimental Botany, Academy Of Sciences Of The Czech Republic	6,9-disubstituted purine derivatives and their use as cosmetics and cosmetic compositions
US7894450B2 (en)	2007-12-31	2011-02-22	Nortel Network, Ltd.	Implementation of VPNs over a link state protocol controlled ethernet network
BRPI0906474A2 (pt)	2008-01-04	2015-07-14	Intellikine Inc	Certas entidades químicas, composições e métodos
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US20090181920A1 (en)	2008-01-09	2009-07-16	Pgxhealth, Llc	Intrathecal treatment of neuropathic pain with a2ar agonists
WO2009088086A1 (ja)	2008-01-10	2009-07-16	Asahi Glass Company, Limited	ガラス、発光装置用の被覆材および発光装置
WO2009089598A2 (en)	2008-01-18	2009-07-23	Katholieke Universiteit Leuven	Msmb-gene methylation based diagnosis, staging and prognosis of prostate cancer
NZ586399A (en)	2008-01-24	2011-12-22	Ucb Pharma Sa	Compounds comprising a cyclobutoxy group
CA2710929A1 (en)	2008-01-28	2009-08-06	Schering Corporation	Imidazopyrazines as protein kinase inhibitors
CN101983062A (zh)	2008-02-07	2011-03-02	吉利德帕洛阿尔托股份有限公司	提高abca-1的化合物及其用途
WO2009100406A2 (en)	2008-02-07	2009-08-13	Synta Pharmaceuticals Corp.	Topical formulations for the treatment of psoriasis
TWI444384B (zh)	2008-02-20	2014-07-11	Gilead Sciences Inc	核苷酸類似物及其在治療惡性腫瘤上的用途
WO2009114826A2 (en)	2008-03-13	2009-09-17	Angiodynamics, Inc.	Treatment systems and methods for renal-related diseases
CN101531638B (zh)	2008-03-13	2011-12-28	中国科学院广州生物医药与健康研究院	用作雌激素相关受体调节剂的化合物及其应用
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
EP2288611B1 (en)	2008-03-20	2013-05-15	Amgen Inc.	Aurora kinase modulators and method of use
WO2009118292A1 (en)	2008-03-24	2009-10-01	Novartis Ag	Arylsulfonamide-based matrix metalloprotease inhibitors
CN102333779B (zh)	2008-03-31	2015-12-09	吉宁特有限公司	苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法
FR2929851B1 (fr)	2008-04-09	2012-11-30	Centre Nat Rech Scient	Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
NZ589315A (en)	2008-04-16	2012-11-30	Portola Pharm Inc	2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
GB0808282D0 (en)	2008-05-07	2008-06-11	Medical Res Council	Compounds for use in stabilizing p53 mutants
US8148408B2 (en)	2008-05-09	2012-04-03	Abbott Laboratories	Selective substituted pyridine ligands for neuronal nicotinic receptors
WO2009146406A1 (en)	2008-05-30	2009-12-03	Genentech, Inc.	Purine pi3k inhibitor compounds and methods of use
BRPI0915018A2 (pt)	2008-06-10	2015-10-27	Novartis Ag	compostos orgânicos
US20090312406A1 (en)	2008-06-12	2009-12-17	Hsing-Pang Hsieh	Coumarin compounds and their use for treating viral infection
WO2010006072A2 (en)	2008-07-08	2010-01-14	The Regents Of The University Of California	Mtor modulators and uses thereof
AU2009268611B2 (en)	2008-07-08	2015-04-09	Intellikine, Llc	Kinase inhibitors and methods of use
WO2010009207A1 (en)	2008-07-16	2010-01-21	Schering Corporation	Bicyclic heterocycle derivatives and their use as gpcr modulators
UY31984A (es)	2008-07-16	2010-02-26	Boehringer Ingelheim Int	DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas.
US8450344B2 (en)	2008-07-25	2013-05-28	Aerie Pharmaceuticals, Inc.	Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
WO2010014739A2 (en)	2008-07-29	2010-02-04	Kalypsys, Inc.	Heterocyclic modulators of tgr5
CA2737219C (en)	2008-08-11	2017-02-28	Tracy Keller	Halofuginone analogs for inhibition of trna synthetases and uses thereof
US20100099871A1 (en)	2008-08-15	2010-04-22	Miller Dwight W	Anti-psychotic compounds and pharmaceutical compositions thereof
US8513295B2 (en)	2008-09-23	2013-08-20	Georgetown University	Viral and fungal inhibitors
WO2010036380A1 (en)	2008-09-26	2010-04-01	Intellikine, Inc.	Heterocyclic kinase inhibitors
WO2010046780A2 (en)	2008-10-22	2010-04-29	Institut Pasteur Korea	Anti viral compounds
US9107942B2 (en)	2008-10-31	2015-08-18	University Of Rochester	Methods of diagnosing and treating fibrosis
US8603477B2 (en)	2008-10-31	2013-12-10	Abbvie Biotherapeutics Inc.	Use of anti-CS1 antibodies for treatment of rare lymphomas
US8476282B2 (en)	2008-11-03	2013-07-02	Intellikine Llc	Benzoxazole kinase inhibitors and methods of use
WO2010056758A1 (en)	2008-11-12	2010-05-20	Yangbo Feng	Quinazoline derivatives as kinase inhibitors
US20110269779A1 (en)	2008-11-18	2011-11-03	Intellikine, Inc.	Methods and compositions for treatment of ophthalmic conditions
KR20180117734A (ko)	2008-11-22	2018-10-29	제넨테크, 인크.	유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
AU2009322187B2 (en)	2008-12-04	2015-02-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders
BRPI0922224A2 (pt)	2008-12-08	2016-08-02	Vm Pharma Llc	composições de inibidores de proteína tirosina quiinase receptora.
BRPI0922226A2 (pt)	2008-12-08	2015-12-29	Gilead Connecticut Inc	inibidores de syk imidazopirazina.
US8450321B2 (en)	2008-12-08	2013-05-28	Gilead Connecticut, Inc.	6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
CN102256963B (zh)	2008-12-19	2014-06-11	贝林格尔.英格海姆国际有限公司	作为ccr2受体拮抗剂用于治疗炎症、哮喘和copd的环状嘧啶-4-甲酰胺
WO2010075286A1 (en)	2008-12-24	2010-07-01	University Of Washington	MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
CA2749403A1 (en)	2009-01-13	2010-09-02	Glaxo Group Limited	Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
CN102361640B (zh)	2009-01-13	2016-10-19	范安德尔研究所	异噁唑吡啶酮在制备用于缓解或减轻温血哺乳动物关节炎和哮喘的症状的药物中的用途
GB2480028B (en)	2009-02-04	2013-07-10	Univ Georgia	Methods of inhibiting fibrogenesis and treating fibrotic disease
EP2396315B1 (en)	2009-02-13	2016-08-31	UCB Biopharma SPRL	Quinoline derivatives as pi3k kinase inhibitors
JP5603883B2 (ja)	2009-02-17	2014-10-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｂ−Ｒａｆキナーゼを阻害するためのピリミドピリミジン誘導体
WO2010096680A2 (en)	2009-02-20	2010-08-26	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Protein structural biomarkers to guide targeted chemotherapies
US8591943B2 (en)	2009-04-09	2013-11-26	Merck Sharp & Dohme Corp.	Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
WO2010127208A1 (en)	2009-04-30	2010-11-04	Forest Laboratories Holdings Limited	Inhibitors of acetyl-coa carboxylase
WO2010129816A2 (en)	2009-05-07	2010-11-11	Intellikine, Inc.	Heterocyclic compounds and uses thereof
GB0908957D0 (en)	2009-05-22	2009-07-01	Ucb Pharma Sa	Therapeutic agents
EP2435438A1 (en)	2009-05-27	2012-04-04	Genentech, Inc.	Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
WO2010136491A1 (en)	2009-05-27	2010-12-02	F. Hoffmann-La Roche Ag	Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
EP2438041A4 (en)	2009-06-01	2012-11-21	Merck Sharp & Dohme	PYRAZINE-carboxamide-orexin receptor Antagonist
JP5744859B2 (ja)	2009-06-15	2015-07-08	ライジェルファーマシューティカルズ，インコーポレイテッド	脾臓チロシンキナーゼ（ｓｙｋ）の小分子阻害薬
UA110324C2 (en)	2009-07-02	2015-12-25	Genentech Inc	Jak inhibitory compounds based on pyrazolo pyrimidine
CN101602768B (zh)	2009-07-17	2012-05-30	河南省农科院农副产品加工研究所	一种芝麻素和芝麻林素的提纯方法
EP2459558A2 (en)	2009-07-30	2012-06-06	Irm Llc	Compounds and compositions as syk kinase inhibitors
TW201105669A (en)	2009-07-30	2011-02-16	Irm Llc	Compounds and compositions as Syk kinase inhibitors
EP2286808A1 (en)	2009-08-18	2011-02-23	Rheinische Friedrich-Wilhelms Universität	Cytohesin inhibitors
TWI481601B (zh)	2009-08-21	2015-04-21	Otsuka Pharma Co Ltd	含氮化合物及藥學組成物
BR112012004333A2 (pt)	2009-08-27	2015-09-08	Merck Sharp & Dohme	composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
US20130005802A1 (en)	2009-09-21	2013-01-03	Wei Chen	Treatment of wnt/frizzled-related diseases
JP5791612B2 (ja)	2009-09-23	2015-10-07	メディベイションテクノロジーズ，インコーポレイテッド	ピリド［３，４−ｂ］インドールおよび使用方法
BR112012006639A2 (pt)	2009-09-25	2015-09-08	Vertex Pharma	métodos para preparar derivados de pirimidina úteis como inibidores de protéina quinase
CA2775942A1 (en)	2009-09-29	2011-04-07	Xcovery Holding Company Llc	Pi3k (delta) selective inhibitors
US8106146B2 (en)	2009-10-06	2012-01-31	Medtronic, Inc.	Therapeutic polymers and methods of generation
WO2011047129A1 (en)	2009-10-15	2011-04-21	Southern Research Institute	Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
GB0918249D0 (en)	2009-10-19	2009-12-02	Respivert Ltd	Compounds
JP5904944B2 (ja)	2009-10-22	2016-04-20	フィブロテックセラピューティクスプロプライエタリーリミテッド	縮合環類似体の抗線維症剤
US8637543B2 (en)	2009-11-12	2014-01-28	Ucb Pharma S.A.	Quinoline derivatives as kinase inhibitors
EP2499129B1 (en)	2009-11-12	2014-07-30	UCB Pharma, S.A.	Quinoline and quinoxaline derivatives as kinase inhibitors
WO2011058109A1 (en)	2009-11-12	2011-05-19	Ucb Pharma S.A.	Fused bicyclic pyrrole and imidazole derivatives as kinase inhibitors
EP2512246B1 (en)	2009-12-17	2015-09-30	Merck Sharp & Dohme Corp.	Aminopyrimidines as syk inhibitors
US8759366B2 (en)	2009-12-17	2014-06-24	Merck Sharp & Dohme Corp.	Aminopyrimidines as SYK inhibitors
WO2011075628A1 (en)	2009-12-18	2011-06-23	Amgen Inc.	Heterocyclic compounds and their uses
EP2516417B1 (en)	2009-12-22	2017-10-11	Vertex Pharmaceuticals Incorporated	Isoindolinone inhibitors of phosphatidylinositol 3-kinase
AU2010333804B2 (en)	2009-12-23	2015-07-16	Takeda Pharmaceutical Company Limited	Fused heteroaromatic pyrrolidinones as syk inhibitors
WO2011103016A2 (en)	2010-02-19	2011-08-25	The Regents Of The University Of Michigan	Compositions and methods for inhibiting ezh2
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
DE102010013716A1 (de)	2010-03-31	2011-10-06	Rheinische Friedrich-Wilhelms-Universität Bonn Körperschaft des öffentlichen Rechts	Verwendung von Cytohesin-Inhibitoren
CN102985927B (zh)	2010-04-29	2019-03-15	加利福尼亚大学董事会	利用关于基因组模型的数据集成的途径识别方法(paradigm)
GB201007203D0 (en)	2010-04-29	2010-06-16	Glaxo Group Ltd	Novel compounds
JP5951600B2 (ja)	2010-05-21	2016-07-13	インフィニティーファーマシューティカルズ，インコーポレイテッド	キナーゼ調節のための、化合物、組成物および方法
WO2011150201A2 (en)	2010-05-27	2011-12-01	Ambit Biosciences Corporation	Azolyl amide compounds and methods of use thereof
WO2012009097A1 (en)	2010-06-17	2012-01-19	Cytokinetics, Inc.	Methods of treating lung disease
US20130195843A1 (en)	2010-06-23	2013-08-01	British Columbia Cancer Agency Branch	Biomarkers for Non-Hodgkin Lymphomas and Uses Thereof
AU2011298423B2 (en)	2010-09-03	2015-11-05	Bayer Intellectual Property Gmbh	Substituted fused pyrimidinones and dihydropyrimidinones
AR082799A1 (es)	2010-09-08	2013-01-09	Ucb Pharma Sa	Derivados de quinolina y quinoxalina como inhibidores de quinasa
AU2011298987B2 (en)	2010-09-10	2017-09-28	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en)	2010-09-10	2015-11-03	Epizyme, Inc.	Inhibitors of human EZH2, and methods of use thereof
AR082985A1 (es) *	2010-09-14	2013-01-23	Exelixis Inc	INHIBIDORES DE PI3K-d Y METODOS DE SU USO Y PREPARACION
CA2812467A1 (en)	2010-09-24	2012-03-29	Gilead Calistoga Llc	Atropisomers of pi3k-inhibiting compounds
US8765773B2 (en)	2010-10-18	2014-07-01	Millennium Pharmaceuticals, Inc.	Substituted hydroxamic acids and uses thereof
UY33337A (es)	2010-10-18	2011-10-31	Respivert Ltd	DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP3176154B1 (en)	2010-11-01	2019-02-20	Portola Pharmaceuticals, Inc.	Benzamides and nicotinamides as syk modulators
WO2012061696A1 (en)	2010-11-04	2012-05-10	Amgen Inc.	5 -cyano-4, 6 -diaminopyrimidine or 6 -aminopurine derivatives as pi3k- delta inhibitors
AU2011326427B2 (en)	2010-11-10	2016-01-07	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
WO2012065057A2 (en)	2010-11-12	2012-05-18	Exelixis, Inc.	Phosphatidylinositol 3-kinase inhibitors and methods of their use
WO2012065019A2 (en)	2010-11-12	2012-05-18	Exelixis, Inc.	Pyridopyrimidinone inhibitors of p13k alpha
JP6154746B2 (ja)	2010-12-08	2017-06-28	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	グルコセレブロシダーゼ活性剤としての置換ピラゾロピリミジン類
GB201021104D0 (en)	2010-12-13	2011-01-26	Univ Leuven Kath	Novel compounds for the treatment of neurodegenerative diseases
CN103648499B (zh)	2011-01-10	2017-02-15	无限药品股份有限公司	用于制备异喹啉酮的方法及异喹啉酮的固体形式
JP2012184225A (ja)	2011-02-18	2012-09-27	Otsuka Pharmaceut Co Ltd	医薬組成物
CA2827311A1 (en)	2011-02-18	2012-08-23	Vertex Pharmaceuticals Incorporated	Chroman-spirocyclic piperidine amides as modulators of ion channels
ES2533042T3 (es)	2011-02-25	2015-04-07	Takeda Pharmaceutical Company Limited	Oxazinopteridinas y oxazinopteridinonas N-sustituidas
JP5569437B2 (ja)	2011-03-09	2014-08-13	コニカミノルタ株式会社	光学フィルム及びそれを用いた偏光板、液晶表示装置
US9029389B2 (en)	2011-04-21	2015-05-12	Institut Pasteur Korea	Anti-inflammation compounds
JP5934782B2 (ja)	2011-05-04	2016-06-15	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	アミノ−ピリジン含有脾臓チロシンキナーゼ（Ｓｙｋ）阻害薬
CN105693645B (zh)	2011-05-10	2018-10-09	吉利德科学公司	作为离子通道调节剂的稠合杂环化合物
JP2013010734A (ja)	2011-06-03	2013-01-17	Sumitomo Chemical Co Ltd	Ｎ−置換ラクタム化合物の製造方法
AU2012272815B2 (en)	2011-06-22	2017-09-07	The General Hospital Corporation	Treatment of proteinopathies
US8716297B2 (en)	2011-07-15	2014-05-06	Abbvie Inc.	Chemical entities to be used for Wee1 inhibition for the treatment of cancer
US8969363B2 (en)	2011-07-19	2015-03-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013012918A1 (en) *	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
TW201311663A (zh)	2011-08-29	2013-03-16	Infinity Pharmaceuticals Inc	雜環化合物及其用途
WO2013038381A1 (en)	2011-09-16	2013-03-21	Novartis Ag	Pyridine/pyrazine amide derivatives
SG11201401082XA (en)	2011-09-30	2014-04-28	Kineta Inc	Anti-viral compounds
JP2015027951A (ja)	2011-11-02	2015-02-12	日本農薬株式会社	フタルアミド誘導体及び該誘導体を含有する農園芸用殺虫剤並びにその使用方法
WO2013082540A1 (en)	2011-12-02	2013-06-06	Gilead Calistoga Llc	Compositions and methods of treating a proliferative disease with a quinazolinone derivative
EP2834244B1 (en)	2012-03-13	2016-08-10	Respivert Limited	Crystalline pi3 kinase inhibitors
WO2013154870A1 (en)	2012-04-10	2013-10-17	Annji Pharmaceutical Co., Ltd.	Histone deacetylases (hdacs) inhibitors
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2013188432A2 (en)	2012-06-11	2013-12-19	New York University	Asymmetric catalysts
EP2744830A4 (en)	2012-06-21	2015-06-17	Compugen Ltd	ANTI-LSR ANTIBODIES AND THEIR USES FOR THE TREATMENT OF CANCER
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
US9562034B2 (en)	2012-08-30	2017-02-07	The University Of Tokyo	Endoparasite control agent
US20140120083A1 (en)	2012-11-01	2014-05-01	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
US20140120060A1 (en)	2012-11-01	2014-05-01	Infinity Pharmaceuticals, Inc.	Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
AU2014205577A1 (en)	2013-01-10	2015-05-28	Nimbus Iris, Inc.	IRAK inhibitors and uses thereof
US20140275082A1 (en)	2013-03-14	2014-09-18	Abbvie Inc.	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014165827A1 (en)	2013-04-05	2014-10-09	Salk Institute For Biological Studies	Ppar agonists
UY35675A (es)	2013-07-24	2015-02-27	Novartis Ag	Derivados sustituidos de quinazolin-4-ona
WO2015048318A1 (en)	2013-09-25	2015-04-02	Vertex Pharmaceuticals Incorporated	A selective inhibitor of phosphatidylinositol 3-kinase-gamma
EP3964507A1 (en)	2013-10-04	2022-03-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN105979948A (zh)	2013-12-05	2016-09-28	安塞塔制药公司	Pi3k抑制剂和btk抑制剂的治疗组合
TWI672297B (zh)	2013-12-18	2019-09-21	義大利商吉斯藥品公司	作為磷脂肌醇－３－激酶抑制劑之異唏衍生物
NZ720867A (en)	2013-12-20	2018-01-26	Gilead Calistoga Llc	Process methods for phosphatidylinositol 3-kinase inhibitors
US9775844B2 (en) *	2014-03-19	2017-10-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
MX387318B (es)	2014-04-14	2025-03-18	Arvinas Operations Inc	Moduladores de la proteólisis basados en imida y métodos de uso asociados.
US10544360B2 (en)	2014-09-24	2020-01-28	Merck Patent Gmbh	Materials for organic electroluminescent devices
US9708348B2 (en)	2014-10-03	2017-07-18	Infinity Pharmaceuticals, Inc.	Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
WO2016057322A1 (en)	2014-10-08	2016-04-14	Salk Institute For Biological Studies	Ppar agonists and methods of use thereof
US10144724B2 (en)	2015-07-22	2018-12-04	Araxes Pharma Llc	Substituted quinazoline compounds and methods of use thereof
GB201513614D0 (en)	2015-07-31	2015-09-16	Univ College Cork Nat Univ Ie	Compositions, compounds and methods and uses relating thereto
HK1261923A1 (zh) *	2015-09-14	2020-01-10	Twelve Therapeutics, Inc.	异喹啉酮衍生物的固体形式、其制备方法、包含其的组合物及其使用方法
CN106632243B (zh)	2015-10-28	2019-03-15	华领医药技术（上海）有限公司	吡咯烷衍生物
EP3394056B1 (en)	2015-12-22	2021-04-14	Shy Therapeutics LLC	Compounds for the treatment of cancer and inflammatory disease
US10759806B2 (en)	2016-03-17	2020-09-01	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
CN107344931B (zh)	2016-05-06	2020-09-15	上海迪诺医药科技有限公司	苯并氮杂卓衍生物、其制备方法、药物组合物及应用
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PL3490565T3 (pl)	2016-07-29	2022-09-26	Rapt Therapeutics, Inc.	Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
KR102497742B1 (ko)	2016-08-30	2023-02-10	다나-파버 캔서 인스티튜트 인크.	약물 전달 조성물 및 그의 용도
WO2018049271A1 (en)	2016-09-09	2018-03-15	Flx Bio, Inc.	Chemokine receptor modulators and uses thereof
US20180154142A1 (en)	2016-12-05	2018-06-07	Old Dominion University Research Foundation	Methods and devices for treatment of tumors with nano-pulse stimulation
JP2020503289A (ja)	2016-12-14	2020-01-30	ターベダセラピューティクスインコーポレイテッドＴａｒｖｅｄａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｈｓｐ９０標的化コンジュゲート及びその製剤
US20190070166A1 (en)	2017-09-02	2019-03-07	Richard Postrel	Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease
CN108658937A (zh)	2017-03-28	2018-10-16	中国海洋大学	一种双环生物碱类化合物及其制备方法和应用
MA49458A (fr)	2017-06-21	2020-04-29	SHY Therapeutics LLC	Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
WO2018237007A1 (en)	2017-06-22	2018-12-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR THE TREATMENT OF CANCER
SG11202000523PA (en)	2017-07-31	2020-02-27	The Trustees Of Columbia Univeristy In The City Of New York	Compounds, compositions, and methods for treating t-cell acute lymphoblastic leukemia
EP3450441B1 (en)	2017-09-05	2020-12-23	Samsung Electronics Co., Ltd.	Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound
KR20200078495A (ko)	2017-09-26	2020-07-01	더 리전트 오브 더 유니버시티 오브 캘리포니아	암 치료를 위한 조성물 및 방법
EP3723811A4 (en)	2017-12-14	2021-09-01	Tarveda Therapeutics, Inc.	TARGETING HSP90 CONJUGATES AND FORMULATIONS OF THE LATTER
CN108310384B (zh)	2018-02-05	2021-06-15	苏州大学	Pi3k抑制剂在制备治疗血小板数量减少相关疾病药物中的用途
US20210069230A1 (en)	2018-04-13	2021-03-11	The Broad Institute, Inc.	Synergistic drug combinations predicted from genomic features and single-agent response profiles
WO2019228404A1 (zh)	2018-05-31	2019-12-05	信达生物制药(苏州)有限公司	一种新型磷酸肌醇3-激酶抑制剂及其制备方法和用途
TWI869347B (zh)	2018-06-19	2025-01-11	美商百歐恩泰美國公司	新抗原及其用途
US20200085925A1 (en)	2018-07-26	2020-03-19	Atyr Pharma Inc.	Compositions and methods for treating nrp2-associated diseases
EP3836929A1 (en)	2018-08-14	2021-06-23	Camp4 Therapeutics Corporation	Methods of treating liver diseases
CN110833546B (zh)	2018-08-17	2022-06-28	中国科学院分子细胞科学卓越创新中心	通佐溴胺在治疗胃癌中的用途
EP3856786A4 (en)	2018-09-28	2022-07-20	Imaginab, Inc.	CD8 IMAGING CONSTRUCTS AND METHODS OF USE
US20210338681A1 (en)	2018-10-01	2021-11-04	Secura Bio, Inc.	Combination therapies
WO2020081549A1 (en)	2018-10-15	2020-04-23	The Regents Of The University Of California	Methods and materials for assessing and treating cancer
MY205142A (en)	2018-10-31	2024-10-03	Gilead Sciences Inc	Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
TW202136261A (zh)	2018-10-31	2021-10-01	美商基利科學股份有限公司	經取代之6-氮雜苯并咪唑化合物
KR20210107069A (ko)	2018-12-21	2021-08-31	다이이찌 산쿄 가부시키가이샤	항체-약물 컨쥬게이트와 키나아제 저해제의 조합
US20220153791A1 (en)	2019-02-13	2022-05-19	Vasgene Therapeutics Inc	Ephb4-ephrin b2 receptor ligand pair as a novel marker for the treatment of prostate cancer
US20220362381A1 (en)	2019-02-21	2022-11-17	Bambu Vault Llc	Remotely triggered therapy
WO2020176501A1 (en)	2019-02-25	2020-09-03	Albert Einstein College Of Medicine	Compounds useful for inhibiting raf dimers
CA3134173A1 (en)	2019-04-10	2020-10-15	Nanjing Zhengxiang Pharmaceuticals Co., Ltd.	Phosphatidylinositol 3-kinase inhibitors
TWI826690B (zh)	2019-05-23	2023-12-21	美商基利科學股份有限公司	經取代之烯吲哚酮化物及其用途
WO2020251974A1 (en)	2019-06-10	2020-12-17	Kymera Therapeutics, Inc.	Smarca inhibitors and uses thereof
WO2020257412A1 (en)	2019-06-19	2020-12-24	Orionis Biosciences, Inc.	Combination therapy with cd13-targeted chimeric proteins or chimeric protein complexes
CN112194659A (zh)	2019-07-08	2021-01-08	浙江海正药业股份有限公司	炔类衍生物及其制备方法和用途
US20210017607A1 (en)	2019-07-18	2021-01-21	The University Of Chicago	Methods of Predicting Responsiveness to Cancer Therapies
WO2021024191A2 (en)	2019-08-05	2021-02-11	Bristol-Myers Squibb Company	Combination treatments with benzodiazepinone compounds and phosphoinositide 3-kinase pathway inhibitors for treating cancer
CN112409331B (zh)	2019-08-21	2024-02-20	上海翰森生物医药科技有限公司	杂环类衍生物抑制剂、其制备方法和应用
US20220348558A1 (en)	2019-09-05	2022-11-03	Wisconsin Alumni Research Foundation	Inhibitors of encephalitic alphaviruses
CN112707905B (zh)	2019-10-25	2024-07-02	武汉誉祥医药科技有限公司	一种三并杂环化合物及其制备方法和用途
WO2021090069A1 (en)	2019-11-07	2021-05-14	In3Bio Ltd.	Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
KR20220094193A (ko)	2019-11-07	2022-07-05	온세르나 테라퓨틱스, 인크.	종양 미세환경의 분류
EP4073516A1 (en)	2019-12-09	2022-10-19	Celcuity Inc.	Methods of treating cancer patients with ras node or rtk targeted therapeutic agents
CN115023224A (zh)	2019-12-20	2022-09-06	里科瑞尔姆Ip控股有限责任公司	组合
WO2021146258A1 (en)	2020-01-14	2021-07-22	The Regents Of The University Of California	Combination therapy for cancer
WO2021149817A1 (en)	2020-01-24	2021-07-29	Taiho Pharmaceutical Co., Ltd.	Enhancement of anti-tumor activity of SHP2 inhibitor pyrimidinone in combination with novel cancer medicines in cancers
WO2021155580A1 (en)	2020-02-07	2021-08-12	Cothera Bioscience, Inc.	Combination therapies and biomarkers for treating cancer
WO2021178595A2 (en)	2020-03-04	2021-09-10	Foundation Medicine, Inc.	Bcor rearrangements and uses thereof
EP3875078A1 (en)	2020-03-06	2021-09-08	Dompe' Farmaceutici S.P.A.	Compounds for the treatment of covid-19
WO2021207230A1 (en)	2020-04-06	2021-10-14	Verastem, Inc.	Methods of treating cytokine release syndrome using a pi3k inhibitor
JP2023524999A (ja)	2020-05-06	2023-06-14	ニューリックスセラピューティクス，インコーポレイテッド	造血前駆体キナーゼの二官能性分解物質およびその治療的使用
WO2021242859A1 (en)	2020-05-27	2021-12-02	Duke University	Compositions and methods for sensitizing acute myeloid leukemias to chemotherapy
CN112546025B (zh)	2020-12-09	2023-06-06	武汉理工大学	一种Ce6@CMCS-DSP-IPI549抗肿瘤纳米传递系统的制备方法
CN113143867B (zh)	2020-12-25	2023-09-26	武汉理工大学	一种cmcs-dsp-ipi549抗肿瘤纳米传递系统及其制备方法

2014
- 2014-10-03 EP EP21188077.8A patent/EP3964507A1/en active Pending
- 2014-10-03 PL PL14786409T patent/PL3052485T3/pl unknown
- 2014-10-03 PE PE2016000453A patent/PE20160685A1/es unknown
- 2014-10-03 KR KR1020167011601A patent/KR102365651B1/ko active Active
- 2014-10-03 NZ NZ718430A patent/NZ718430A/en unknown
- 2014-10-03 US US14/506,429 patent/US9359365B2/en active Active
- 2014-10-03 AU AU2014329392A patent/AU2014329392B2/en active Active
- 2014-10-03 ES ES14786409T patent/ES2900806T3/es active Active
- 2014-10-03 SG SG11201602445SA patent/SG11201602445SA/en unknown
- 2014-10-03 PH PH1/2016/500582A patent/PH12016500582B1/en unknown
- 2014-10-03 BR BR112016007467-0A patent/BR112016007467B1/pt active IP Right Grant
- 2014-10-03 PT PT14786409T patent/PT3052485T/pt unknown
- 2014-10-03 JP JP2016519815A patent/JP6466924B2/ja active Active
- 2014-10-03 DK DK14786409.4T patent/DK3052485T3/da active
- 2014-10-03 EP EP14786409.4A patent/EP3052485B1/en active Active
- 2014-10-03 MX MX2021012208A patent/MX2021012208A/es unknown
- 2014-10-03 CA CA2925944A patent/CA2925944C/en active Active
- 2014-10-03 MY MYPI2016701204A patent/MY175778A/en unknown
- 2014-10-03 WO PCT/US2014/059026 patent/WO2015051244A1/en active Application Filing
- 2014-10-03 TW TW103134648A patent/TWI657085B/zh active
- 2014-10-03 HU HUE14786409A patent/HUE057734T2/hu unknown
- 2014-10-03 EA EA201690713A patent/EA201690713A1/ru unknown
- 2014-10-03 UA UAA201604794A patent/UA121104C2/uk unknown
- 2014-10-03 MX MX2016004340A patent/MX389256B/es unknown
- 2014-10-03 SG SG10201902074UA patent/SG10201902074UA/en unknown
- 2014-10-03 CN CN201480066017.5A patent/CN105793255B/zh active Active
2015
- 2015-04-24 US US14/695,699 patent/US9828377B2/en active Active
2016
- 2016-03-29 IL IL244818A patent/IL244818B/en unknown
- 2016-04-04 CL CL2016000783A patent/CL2016000783A1/es unknown
- 2016-04-04 ZA ZA2016/02220A patent/ZA201602220B/en unknown
2017
- 2017-10-26 US US15/794,816 patent/US10329299B2/en active Active
2019
- 2019-05-20 US US16/417,420 patent/US20190367521A1/en not_active Abandoned
2021
- 2021-03-15 US US17/202,195 patent/US12152032B2/en active Active
- 2021-10-26 CY CY20211100926T patent/CY1124998T1/el unknown
2024
- 2024-10-23 US US18/924,603 patent/US20250171453A1/en active Pending

Also Published As

Publication number	Publication date
MY175778A (en)	2020-07-08
CA2925944C (en)	2023-01-10
AU2014329392B2 (en)	2018-12-20
CN105793255A (zh)	2016-07-20
DK3052485T3 (da)	2021-10-11
JP2016536283A (ja)	2016-11-24
EP3964507A1 (en)	2022-03-09
TWI657085B (zh)	2019-04-21
WO2015051244A1 (en)	2015-04-09
KR102365651B1 (ko)	2022-02-21
MX2016004340A (es)	2016-08-08
PT3052485T (pt)	2021-10-22
ES2900806T3 (es)	2022-03-18
EA201690713A1 (ru)	2016-08-31
PL3052485T3 (pl)	2022-02-28
CN105793255B (zh)	2018-11-16
IL244818B (en)	2021-08-31
BR112016007467A2 (pt)	2017-08-01
NZ718430A (en)	2021-12-24
CY1124998T1 (el)	2023-01-05
PH12016500582B1 (en)	2023-06-30
US20150225410A1 (en)	2015-08-13
EP3052485B1 (en)	2021-07-28
PH12016500582A1 (en)	2016-05-16
BR112016007467B1 (pt)	2022-09-20
MX2021012208A (es)	2023-01-19
US20150111874A1 (en)	2015-04-23
US20220372038A1 (en)	2022-11-24
US9828377B2 (en)	2017-11-28
PE20160685A1 (es)	2016-07-23
US20190367521A1 (en)	2019-12-05
UA121104C2 (uk)	2020-04-10
CL2016000783A1 (es)	2017-05-19
US20250171453A1 (en)	2025-05-29
US20180044346A1 (en)	2018-02-15
US9359365B2 (en)	2016-06-07
US10329299B2 (en)	2019-06-25
SG10201902074UA (en)	2019-04-29
CA2925944A1 (en)	2015-04-09
SG11201602445SA (en)	2016-04-28
KR20160068832A (ko)	2016-06-15
IL244818A0 (en)	2016-05-31
ZA201602220B (en)	2018-05-30
JP6466924B2 (ja)	2019-02-06
TW201605829A (zh)	2016-02-16
MX389256B (es)	2025-03-20
EP3052485A1 (en)	2016-08-10
US12152032B2 (en)	2024-11-26

Publication	Publication Date	Title
HUE057734T2 (hu)	2022-06-28	Heterociklusos vegyületek és alkalmazásuk
HRP20181392T1 (hr)	2018-10-19	Heterociklični spojevi i njihova uporaba
IL243420A0 (en)	2016-02-29	Heterocyclic compounds and their uses
DK2968173T3 (da)	2020-12-21	Heterocykliske forbindelser og anvendelser deraf
DK3052140T3 (da)	2019-06-11	Ikke-selvklæbende coatingmaterialer
DK3063144T3 (da)	2021-10-25	Antiparasitære og pesticid-isoxazolinforbindelser
HUE061179T2 (hu)	2023-05-28	Szárító kompozíció és alkalmazása
DK3030549T3 (da)	2019-05-13	Pyridazinonforbindelser og anvendelser deraf
LT3038654T (lt)	2020-01-27	Naujas panaudojimas
EP2987933A4 (en)	2016-12-21	HINGE
PL3030519T3 (pl)	2022-05-23	Trójpierścieniowe związki benzoksaborolu i ich zastosowania
HUE059507T2 (hu)	2022-11-28	BAFF-ra és B7RP1-re specifikus fehérjék és alkalmazásuk
DK3066089T3 (da)	2020-01-27	Substituerede n-acetyl-l-cysteinderivater og relaterede forbindelser
HRP20190133T1 (hr)	2019-03-22	Heterociklički spoj
FR3007291B1 (fr)	2015-07-17	Composition cicatrisante et utlisation
TH1501003198A (th)	2016-12-02	สารประกอบเฮเทอโรไซคลิค
TH1401007376A (th)	2016-06-07	ไดอะซาสไปโรไซโคลแอลเคนและอะซาสไปโรไซโคลแอลเคนชนิดใหม่
TH148825B (th)	2016-04-18	สารประกอบเตตระโซลิโนนและการใช้ของสิ่งนั้น
TH148368B (th)	2016-04-01	อนุพันธ์ไธอะโซลคาร์บอกแซมีดชนิดใหม่และวิธีใช้สารเหล่านั้น
ES1082404Y (es)	2013-09-16	Cartera
ES1080079Y (es)	2013-08-26	Cartera
UA25783S (uk)	2013-11-11	Шарнір